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Huntington’s disease (HD) is a fatal neurodegenerative disorder for which there are no 
therapeutic treatments. Previous studies have suggested that an increase in SIRT1 
activity might have a neuroprotective effect in mouse models of HD. SIRT1 is a NAD+-
dependent protein deacetylase and plays an important role in neuronal health during 
development, differentiation and ageing. However, the mechanisms controlling SIRT1 
activity and the effect of HD progression on such processes are currently unknown. In 
this study we explored the impact of HD on SIRT1 function in different brain regions of 
the R6/2 (fragment transgenic) and HdhQ150 (knock-in) HD mouse models. We show 
the existence of a striatum-specific age-dependent regulatory mechanism of SIRT1 
activity and a down-regulation of SIRT1 function in the brains of both models. 
Interestingly, we did not detect a co-localization of SIRT1 with mHTT inclusions and to 
further support this finding, we did not observe any reduction of SIRT1 protein level in 
HD brains. In this study, we hypothesize that there is a link between SIRT1 activity and 
SIRT1 phosphorylation status and provide evidence of altered SIRT1 phosphorylation in 
the striatum and cerebellum of HD mice. DBC1 is a negative regulator of SIRT1. We 
found that the ablation of DBC1 did not improve behavioural impairments in R6/2 
mice, suggesting that the mutant HTT-related reduction in SIRT1 activity might lie 
outside the inhibitory circuit controlled by DBC1. Taken together, these data show for 
the first time that there is a striatum-specific mechanism controlling SIRT1 activity via 
phosphorylation in an age-dependent manner and that the SIRT1 function is impaired 
in HD. This work provides insights into the mechanisms that regulate SIRT1 activity in 
the brain, confirms that SIRT1 plays a key role in both the normal and HD brain and 
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Chapter 1  INTRODUCTION 
In 1872 George Huntington described a condition that afflicted a group of his patients. 
He noted that this condition never skipped a generation, causing them to exhibit 
dance-like writhing motions (Huntington, 1872). More than a century on, despite the 
huge effort placed in understanding the pathology known now as Huntington’s disease 
(HD), there are no effective treatments and a cure still remains elusive. 
1.1 Huntington’s Disease 
HD is an inherited neurodegenerative disorder characterized by chorea, behavioural 
manifestations, and dementia (Warby et al., 2011). It is caused by a mutation in the 
huntingtin gene (HTT) and is transmitted in an autosomal dominant manner, thus 
offspring have a 50% chance of inheriting the disease-causing allele should one of their 
parents be HD-positive. Adult-onset HD is the most common form of this disorder with 
onset between 30 and 50 years for most patients and is characterised by a triad of 
psychiatric, cognitive and motor symptoms. Juvenile HD patients usually have a more 
rapid disease progression that is characterised by bradykinesia rather than the typical 
chorea observed in adult onset HD (Bates, Tabrizi and Jones, 2014; Walker, 2007). The 
only therapeutic options currently available to HD patients do not modify disease 
progression, but rather are directed against primary symptoms such as chorea or 
depression. The disease progresses to death 10-20 years after clinical diagnosis.  
 HD is the result of a mutation in HTT which is located within the 4p16.3 locus on 
the short arm of chromosome 4. The HD chromosome was found to contain an 
unstable polymorphic trinucleotide repeat. The polymorphic stretch of the CAG repeat 
resides in the 5’ coding region of the gene and encodes an expanded polyglutamine 
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(polyQ) tract in the 348kD huntingtin protein (HTT) (Huntington's Disease Collaborative 
Research Group, 1993). In humans, the polyQ tract is encoded by a stretch of CAG 
codons that is followed by the sequence CAACAG that also encodes glutamine 
residues. It has been established that it is the length of the CAG repeat that defines 
whether the allele is considered to be in the normal range. In affected individuals the 
CAG repeat number expands from the normal population range (6-35 repeats) to 
greater than 36 repeats. 36–39 repeats result in incomplete penetrance of the disease, 
with a much later onset and slower progression of symptoms. With very large repeat 
counts (40 repeats), HD has full penetrance and can occur under the age of 20, when it 
is then referred to as juvenile (Bates et al., 2014).  
Despite the fact that the huntingtin gene and protein are ubiquitously expressed 
in the human body, the well-described pathology of HD is largely restricted to the 
brain. Post mortem HD brains are characterized by atrophy of the cerebral cortex and 
basal ganglia followed by enlargement of the ventricular space as well as a loss of 
white matter (De la Monte et al., 1988). The cerebral cortex shows a progressive 
atrophy of grey matter, but it is well known that the region most affected by HD 
pathology is the striatum (comprising the caudate and putamen) (Fig. 1). 
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Figure 1. Comparison of coronal sections of brains from an end stage disease HD and 
unaffected individual. Note the pronounced atrophy of the cortex, caudate and 
putamen, enlargement of ventricles and white matter loss. Brain images courtesy 





Chapter 1                                                                                      Introduct ion                                                                                               




The striatum is the main input compartment of the basal ganglia (Fig. 2), and 
comprises a collection of subcortical nuclei involved in the control of movement. The 
striatum receives glutamatergic and dopaminergic innervations from all regions of the 
cerebral cortex, as well as specific thalamic nuclei. The flow of information returns to 
the cortex through the thalamus, the major output structure. Principal motor 
dysfunctions in HD are due to the degeneration of the medium-sized spiny neurons 
(MSNs); these projection neurons represent more than 90% of the striatal cell 
population. Although all MSNs are GABAergic, they differ in a number of properties 
including the expression of dopamine and acetylcholine receptor subtypes, peptide 
content and projection targets. 
 A classical model describes two major neuronal motor pathways, referred to as 
direct and indirect pathways, which act in opposition, and predict the motor 
impairment in HD (Albin et al., 1989). GABAergic neurons at the origin of the direct 
pathway mainly express dopamine D1 and muscarinic M4 receptors, substance P, and 
project to the globus pallidus internal sigments (GPi). On the other hand, GABAergic 
neurons of the indirect pathway mainly express dopamine D2 receptors and 
enkephalin, and project to the globus pallidus external sigments (GPe) (Reiner et al., 
1988; Albin et al., 1991; Richfield et al., 1995; Sapp et al., 1995). The first stage of HD is 
characterized by loss of the projection neurons of the indirect pathway causing an 
imbalance in favour of the direct pathway. Movements are therefore initiated, but 
can’t be controlled (Albin, 1989). At later stages, the general loss of the MSNs, 
including those projecting through the direct pathway, induces a drastic motor 
dysfunction leading to bradykinesia. 
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Figure 2. Scheme of a coronal section of human brain, showing the position of the 
basal ganglia and their different subnuclei. The basal ganglia are composed of four 
principal nuclei: striatum, the globus pallidus (GP) consisting of external and internal 
segments (GPi and GPe), the substantia nigra (SN) consisting of pars compacta and 
reticula (SNc and SNr), and the subthalamic nucleus (STN). Lateral ventricle (VL). 
(Modified from DERIC'S MINDBLOG). 
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In the periphery, the two main hallmarks of HD are progressive weight loss and 
skeletal muscle wasting (Farrer and Meaney, 1985; Saberg et al., 1981). A damaged 
tolerance to glucose and insulin secretion capacity have been observed in patients, as 
well as reduced levels of testosterone and reduced numbers of germ cells in men 
(Bacos et al., 2008; Lalic et al., 2008; Markianos et al., 2005; Van raamsdonk et al., 
2007). The main cause of death is respiratory arrest (Lanska et al., 1988). 
1.2 HTT protein 
The human HTT gene (NP_002102) is translated into a 348 kDa protein. The polyQ 
region, encoded by the CAG stretch, is immediately downstream from amino acid 17 of 
HTT and upstream of a polyproline (polyP) rich region. The polyP region stabilizes the 
polyQ tract and maintains its solubility (Steffan et al., 2004). HTT also contains 36 
Huntingtin (HTT), Elongation factor 3 (EF3), subunit A of protein phosphatase 2A 
(PP2A), Target of Rampamicyn 1 (TOR1) (HEAT) repeats which may promote 
interactions with other proteins and facilitate complex assembly and cellular transport 
(Takano and Gusella, 2002). HEAT repeats have been found predominantly in proteins 
involved in intracellular trafficking and chromosomal segregation but their specific 
function is still unclear. HTT is expressed ubiquitously in humans with the highest levels 
in brain and testis. In the brain the cerebellar cortex, neocortex, striatum and 
hippocampus have the highest levels of HTT (Schmitt et al., 1995). In most cells HTT is 
essentially a cytoplasmic protein associated with various organelles including 
mitochondria, the endoplasmic reticulum and Golgi complex (Di Figlia et al., 1995; 
Trottier et al., 1995). 
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1.3 Function of the HTT protein 
The complete function of the HTT protein has also yet to be fully appreciated. HTT is an 
essential protein involved in early embryonic development (Duyao et al., 1995; Nasir et 
al., 1995; Zeitlin et al., 1995). The deletion of both Htt alleles in mice results in 
embryonic lethality but mice with one functional copy of Htt develop normally. The 
homozygous Knock-out embryos terminate before E8.5 with signs of abnormal 
gastrulation prior to organogenesis and somite formation (Duyao et al., 1995; Nasir et 
al., 1995; Zeitlin et al., 1995). Several studies showed that the loss of Htt expression 
results in embryonic lethality because its absence leads to an impairment of the 
nutritive functions of the visceral endoderm due to the localization of HTT to the 
membranes of vesicles associated with microtubules (Dagastis et al., 1998). This lethal 
phenotype can be rescued by the introduction of embryonic stem cells expressing 
wild-type Htt to support the development and survival of neurons in the mutant 
embryo (Dragatsis et al., 1998; Reiner et al., 2003). Beyond embryonic development, it 
has been shown that HTT is involved in the regulation of gene expression, vesicle 
traffiking and cell survival Zuccato et al., 2003; Gauthier et al., 2004; Dragastis et al., 
2000). 
1.3.1 HTT regulates brain-derived neurotrophic factor expression 
The ability of HTT to regulate gene expression was discovered for the first time 
through analysing the effect of mutant HTT protein (mHTT) expression on 
neurotrophin production. HD pathology involves the selective degeneration of striatal 
neurons, which, in turn, require brain-derived neurotrophic factor (BDNF) for survival 
and differentiation (Mizuno et al., 1994; Ventimiglia et al., 1995; Ivkovic and Ehrlich, 
1999). The major regions of BDNF synthesis are the hippocampus and cortex; the 
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striatum has no  BDNF mRNA and depends, mostly, upon the cortex for the delivery of 
this trophic factor (Altar et al., 1997; Conner et al., 1997). In neuronal cell lines, and 
the brains of transgenic HD mice and HD patients, in addition to a dramatic reduction 
of BDNF mRNA and protein levels, BDNF cortico-striatal anterograde transport has also 
been shown to be altered (Zuccato et al., 2001; Spires et al., 2004a; Pang et al., 2006). 
Reduced transcription of BDNF is attributed to a loss of wild-type HTT function. To 
achieve BDNF transcription, HTT indirectly interacts with the repressor element-1 
transcription factor/neuron restrictive silencer factor complex (REST/NEST) and 
prevents it from entering in the nucleus and binding to the BDNF promoter thereby 
repressing transcription (Zuccato et al., 2003). mHTT is not able to restrict the 
REST/NEST complex to its perinuclear localization and thus, transcription of BDNF is 
repressed (Zuccato et al., 2001). Reduced BDNF cortico-striatal anterograde transport 
has been attributed to the modulation of HTT-HAP1 (huntingtin-associated protein 1) 
binding by the polyQ expansion in mHTT, which reduces the efficiency of Kinesin-1 
dependent transport of BDNF containing-vesicles (Gauthier et al., 2004). HTT 
selectively regulates BDNF expression, indeed, expression of other neurotrophins such 
as nerve growth factor (NGF) and neurotrophin-3 (NT-3) is unaltered in HD. The 
negative effects of mHTT on BDNF transcription are also restricted to neurons since 
mHTT protein does not affect BDNF production in non-neuronal cells such as 
fibroblasts. 
 It is unlikely that reduced BDNF levels are the only contributing factor to the 
degeneration that occurs in HD brain and peripheral tissues. Other factors such as a 
wide-spread transcriptional dysregulation, disrupted protein homeostasis and defects 
in metabolism are all also likely to contribute to the pathogenesis. 
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1.3.2 HTT is involved in vesicular trafficking 
Several studies suggest a role of HTT in vesicular trafficking. HTT facilitates the 
dynein/dynactin-mediated transport of vesicles along microtubules and controls 
cytoskeletal integrity (Diprospero et al., 2004; Gauthier et al., 2004; Caviston et al., 
2007; Johnson et al., 2007a; Smith et al., 2007). There is evidence to suggest that HTT 
promotes the post-Golgi trafficking of various proteins to the plasma membrane 
through an association with acidic phospholipids (Kegel et al., 2005; Strehlow et al., 
2007). The HTT protein has been demonstrated to specifically enhance the transport of 
BDNF-containing vesicles along microtubules via its interaction with HAP-1 and the 
p150(Glued) subunit of dynactin which is an essential component of molecular motors 
(Gauthier et al., 2004). The dynamic protein-protein interaction acts as a molecular 
switch for antero- as well as reterograde transport in neurons (Colin et al., 2008) and 
contributes to the anterograde transport of BDNF from the cortex to the striatum. 
1.3.3 HTT is involved in anti-apoptotic pathways 
HTT promotes cell survival by modulating the signals that trigger programmed cell 
death (apoptosis). HD patients and mouse models possess impaired mitochondrial 
function (Panov et al., 2002; Gines et al., 2003). Both wild-type and mutant HTT are 
associated with the mitochondrial outer membrane (Choo et al., 2004). The calcium 
threshold required to induce mitochondrial permeability transition pore opening can 
be reduced in the presence of mHTT fragments; this causes a release of cytochrome c 
and activation of apoptotic pathways, including the activation of caspases (Choo et al, 
2004), calpain (Bizat et al., 2003), and p53 (Bae et al, 2005). Apoptosis is triggered by 
caspase (cysteine-protease) activity and HTT interacts with caspase-3 (Zhang et al., 
2006). Initiation of caspase-3 activity through tumour-necrosis factor receptor (TNFR) 
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signalling ultimately results in cell death and HTT interacts with activated caspase-3 to 
inhibit this down-stream pro-apoptotic signal. The presence of wild-type HTT is 
essential for regulating caspase-3 mediated signalling as HTT depletion leads to overt 
cell death or increased vulnerability to cell death. Furthermore, the expression of 
expanded polyQ proteins in PC12 cells and in the fibroblasts of HD patients leads to 
the production of reactive oxygen species (ROS) and thus to the activation of the DNA 
damage response (Giuliano, 2003). 
1.4 Molecular pathogenesis of HD 
A complete picture of the normal activities of HTT has not yet been determined. This is 
essentially because the protein is a very large, making isolation and analysis difficult. 
Moreover, HTT is found ubiquitously in different tissues, interacting with hundreds of 
partners (Harjes and Wanker, 2003; Li and Li, 2004; Borrell-Pages et al., 2006a; 
Kaltenbach et al., 2007). 
As a consequence of HTT interactions with proteins of diverse biological roles, HTT has 
been implicated in many processes including transcriptional regulation, RNA splicing, 
signal transduction, intracellular trafficking, cytoskeletal organization as well as protein 
folding and turnover (Li and Li, 2004). It is, therefore, not surprising that many 
pathways, cycles, cascades or mechanisms appear to be affected by the presence of 
mHTT (Fig. 3). 
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Figure 3. Description of main events contributing to HD pathogenesis. 
mHTT is proteolytically cleaved in the cytoplasm (A). Chaperones attempt to re-fold or 
target mHTT for proteaosomal or autophagic degradation, however, the system is 
inefficient and mHTT aggregates in the cytoplasm and nucleus. (B) PolyQ expansion 
leads to mHTT and N-terminal fragments abnormally interacting with proteins and 
organelle membranes, causing defects in Ca2+ signalling (C) and mitochondrial 
dysfunction (D). (E) N-terminal mHTT fragments translocate to the nucleus where they 
impair transcription and form intranuclear inclusions. (F) mHTT also causes defects in 
vesicle transport, recycling and neuronal signalling. Image reproduced from (Zuccato et 
al., 2010). 
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1.4.1 Loss of function and gain of function of  the HTT protein 
The hypothesis that a loss of normal HTT function may play a role in HD pathology 
followed the finding that HTT is an indispensable protein with antiapoptotic functions 
(Rigamonti et al., 2000). Indeed, it has been shown that the overexpression of wild-
type HTT can have a neuroprotective role in striatal cells exposed to various apoptotic 
stimuli (Rigamonti et al., 2001). Moreover, the postnatal inactivation of HTT in mouse 
neurons resulted in a progressive degenerative neuronal phenotype, further 
supporting the role of HTT in the survival of adult neurons (Dragatsis et al., 2000). 
Previous studies showed that HTT has an antiapoptotic function through interacting 
and inhibiting molecules such as Huntingtin Interacting Protein 1 (HIP1) that, once 
dissociated from HTT activates caspase 8 (Gervais et al., 2002). The protection of wild-
type HTT may also occur by activation of BDNF transcription through the interaction 
with REST and by the stimulation of the vesicular BDNF transport along microtubules 
(Zuccato et al., 2001; Zuccato et al., 2003; Gauthier et al., 2004). 
 The events and mechanisms that lead to HD pathological signs have also been 
attributed to a toxic gain-of-function conferred to mHTT through the expanded polyQ 
tract, supported by various data. mHTT has been found to rescue the embryonic 
lethality of knock-out in Htt in the mouse, indicating that the HD mutation does not 
impair normal embryonic HTT functions (Duyao et al., 1995; Nasir et al., 1995).  The 
toxic gain of function scenario is further supported by the fact that similar symptoms 
and molecular abnormalities are also displayed by patients and models of other polyQ 
expansion disorders, summarized in Table 1. Although the polyQ expansion occurs in 
functionally and structurally different proteins, these all share the common strong 
propensity for aggregation. It has been proposed that elongated polyQ tracts promote 
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the formation of expanded beta sheet conformations in proteins, these then form 
parallel alignments of beta-sheet structures which drive proteins aggregation (Perutz 




Table.1: Polyglutamine disorders. HD: Huntington's disease is caused by expansion of 
a translated CAG repeat located in the N-terminus of HTT; SCAs (1, 2, 3, 6, 7 and 17): 
Spinocerebellar ataxias are caused by expansion of a translated CAG repeat. Ataxin-1, 
2, 3, and 7 are the proteins implicated in SCA1, 2, 3, and 7, respectively, whereas the 
α1A subunit of the voltage-dependent calcium channel (CACNA1A), the TATA-binding 
protein (TBP) are implicated in SCA6 and SCA17, respectively; SBMA: Spinal and bulbar 
muscular atrophy is caused by expansion of a CAG repeat in the first exon of the 
androgen receptor gene; DRPLA: Dentatorubral-pallidoluysian atrophy is by the 












Main clinical features 
HD 143100 Huntingtin 6–34 36–121 Chorea, dystonia, cognitive 
deficits, psychiatric problems 
SCA1 164400 Ataxin1 6–44 39–82 Ataxia, slurred speech, 
spasticity, cognitive 
impairments 
SCA2 183090 Ataxin2 15–24 32–200 Ataxia, polyneuropathy, 
decreased reflexes, infantile 
variant with retinopathy 
SCA3 109150 Ataxin3 13–36 61–84 Ataxia, parkinsonism, 
spasticity 
SCA6 183086 CACNA1A 4–19 10–33 Ataxia, dysarthria, nystagmus, 
tremors 
SCA7 164500 Ataxin7 4–35 37–306 Ataxia, blindness, cardiac 
failure in infantile form 
SCA17 607136 TBP 25–42 47–63 Ataxia, cognitive decline, 
seizures, and psychiatric 
problems 
SBMA 313200 Androgen 
receptor 
9–36 38–62 Motor weakness, swallowing, 
gynecomastia, decreased 
fertility 
DRPLA 125370 Atrophin 7-34 49-88 Ataxia, seizures, 
choreoathetosis, dementia 
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1.4.2 Post-translational modifications of HTT 
As described previously, HTT is a large protein characterized by several post-
translational modification sites which affect its localization, longevity and/or toxicity. 
For example, there are three lysine (K) residues at the amino(N)-terminus (K6, K9 and 
K15) that can be either ubiquinated (promoting HTT degradation) or sumoylated 
(resulting in HTT nuclear localisation) (Steffan et al., 2004). Phosphorylation of HTT 
occurs at one threonine (T3) and several serine (S13, S16, S421, S434, S536, S1181, 
S1201, S2076, S2653 and S2657) residues and its outcome can have varying effects 
depending on the residue in question; this ranges from protection via modulating 
proteolytic cleavage (S421, S434, S536) (Luo et al., 2005; Schilling et al., 2006; Warby 
et al., 2009) through to proteosomal targeting (S13 and S16) (Thomson et al., 2009), 
and modulation of vesicle transport (S421) (Zala et al., 2008). 
Acetylation sites have been identified at K9, K178, K236, K345 and K444 (Cong et al., 
2011), and it has been demonstrated that the acetylation at K444 promotes the 
targeting of HTT for degradation by autophagy (Jeong et al., 2009). HTT is also 
palmitoylated at cysteine 214, which is in line with its proposed role in vesicle 
trafficking (Yanai at al., 2006).  
1.4.3 Proteolytic cleavage and protein aggregation  
mHTT is very sensitive to the proteolytic cleavages that generate small toxic N-terminal 
fragments. It has been proposed that full length HTT is proteolytically processed into 
smaller toxic N-terminal fragment by caspases, calpains, and matrix 
metalloproteinases, which can then translocate to the nucleus to exert a toxic effect 
(Benn et al., 2005; Landles et al., 2010; Miller et al., 2010). The cleavage of HTT into 
fragments containing the polyQ stretch, and their subsequent translocation to the 
Chapter 1                                                                                      Introduct ion                                                                                               




nucleus, is likely to be a key step in disease progression (Saudou et al., 1998).  Such 
fragments have a strong propensity to aggregate in the cell, producing different 
oligomeric species and insoluble aggregates capable of capturing and inactivating 
proteins essential for normal cell function. Recent data have shown that CAG repeat 
length–dependent aberrant splicing of exon 1 HTT results in a short polyadenylated 
mRNA that is translated into an exon 1 HTT protein (Sathasivam et al., 2013). 
N-terminal HTT fragments have been identified in neuronal intranuclear inclusions 
(NIIs) of HD postmortem brains (Fig. 4) (DiFiglia et al., 1997). Previous studies suggest 
that not all the N-terminal fragments resulting from proteolysis are toxic. For example, 
mice expressing mHTT, resistant to cleavage by caspase 6, but not caspase 3, are 
characterized by a normal neuronal function and do not develop striatal 
neurodegeneration (Graham et al., 2006). Indeed, while mHTT cleavage and the 
formation of inclusions occur both in transgenic animals and in HD patients (Sieradzan 
et al., 1999), their contribution to HD pathology is still debated. 
An association between mHTT aggregates and neuronal dysfunction has been 
demonstrated. Indeed, the accumulation of large aggregates has been proven to 
sequester vital cellular proteins, including transcription factors and protein quality 
control components, supporting for their toxic role in HD pathogenesis (Hay et al., 
2004; Jiang et al., 2003; Morton and Edwardson, 2001; Steffan et al., 2000). 
Interestingly, however, studies have demonstrated that when motor symptoms were 
ameliorated in R6/2 mice, a concomitant reduction of aggregate load was observed 
(Mielcarek et al., 2014; Labbadia et al., 2011; 2012). In addition, it has been shown, 
when proteolysis is prevented by inhibition of caspase or calpain activity or by 
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modifying the consensus cleavage site in HTT, mHTT toxicity is reduced and disease 
progression is slowed (Gafni et al., 2004; Luo et al., 2005; Graham et al., 2006).  
 Neuronal Intranuclear Inclusions (NIIs) are a pathological hallmark of both HD 
and various other polyQ disorders. It is well known that these structures are dynamic 
and that the pathway from soluble HTT to inclusion bodies formation is a multi-step 
process whereby many different species are formed before the mature inclusion. In 
contrast, some studies have suggested that inclusion formation alone is not sufficient 
to cause cortical or striatal pathology in mice (Gu et al., 2005; 2007). Work in cell 
culture models has shown that the formation of large nuclear inclusions correlated 
with survival and that cell death was best predicted by the presence of smaller 
oligomeric species (Arrasate at al., 2004; Miller et al., 2011). These results have led 
some to suggest that the detergent-soluble oligomeric species could be more reactive 
and toxic than large, insoluble inclusions. In this scenario, cells could be promoting the 
assembly of small toxic oligomers into large, inert inclusions thereby minimising their 
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Figure 4. Huntingtin immunoreactivity in HD post-mortem brain. (A) Cortex of a 
juvenile patient shows numerous inclusions prominently stained. (B) Cortical neurons 
containing one inclusion. (C) Striatal neurons with inclusions. Reproduced from (Di 
Figlia et al., 1997) 
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1.4.4 Protein quality control: HSR, UPS, Autophagy and ER stress in HD 
It has been showed that a polyQ expansion induces mHTT to undergo a conformational 
change that causes it to misfold. Recent data have shown that the Heat shock response 
(HSR) is inefficient in its ability to degrade the misfolded mHTT. Indeed, a study 
conducted in our laboratory demonstrated that the HSR is impaired in R6/2 and 
HdhQ150 mice (Labbadia et al., 2011). Interestingly, the same study showed that 
pharmacological stimulation of the HSR only transiently improved behavioural 
phenotype, due to an impairment of the HSR with disease progression.  
 If mHTT cannot be properly refolded it should be eliminated by the ubiquitin- 
proteasome system (UPS). Indeed, ubiquitin has been found to be associated with 
mHTT (Davies et al., 1999), suggesting that the UPS attempts to target mHTT for 
degradation but fails to execute the final steps (Gutekunst et al., 1999).Whether the 
impairment of the UPS is, in part, responsible for the HD pathology, remains 
contentious but HD post mortem brain samples show decreased proteasome activity 
and this has been confirmed with patient fibroblast and other cell culture models 
(Bence et al., 2001; Bennett et al., 2005; Seo et al., 2004). 
A number of studies have shown that autophagy plays a central role in degradation of 
unfolded proteins (Ravikumar et al., 2002; Rubinsztein et al., 2006; Settembre et al., 
2008). Autophagy is a degradation process aimed at the clearance of long-lived 
proteins, protein complexes and organelles. There is evidence to suggest that the 
autophagy process is abnormal in HD brain as well as in cellular and animal models 
(Larsen et al., 2002; Kegel et al., 2000; Petersen et al., 2001). Furthermore, inhibition of 
the autophagy process causes a neurodegenerative phenotype in mice, and induction 
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of autophagy, by treatment with the mTOR inhibitor (rapamycin), reduced aggregation 
and attenuated toxicity in cells and mouse models of HD (Ravikumar et al., 2004).  
 Evidence is beginning to emerge to indicate that the clearance pathways 
responsible for eliminating aggregates are closely regulated by the ER through the UPR 
(Unfolded Protein Response) stress sensors, such as IRE1and PERK/eIF2(Kouroku 
et al., 2007). Studies aimed at understanding the function of wild-type HTT 
demonstrated that inhibition of its expression significantly alters the ER 
morphogenesis (Hilditch-Maguire et al., 2000; Omi et al., 2005). In addition, mHTT 
perturbs ER calcium homeostasis (Rockabrand et al., 2007). Thus, increasing evidence 
suggests that mHTT may exert its neurotoxic effect through directly inducing ER stress. 
Indeed, the accumulation of mHTT inclusions has been shown to trigger activation of 
the UPR in vitro (Kouroku et al., 2007; Reijonen et al., 2008) and subsequently the 
autophagic clearance of such aggregates (Kouroku et al., 2007; Hoyer-Hansen et al., 
2007, Hoyer-Hansen et al., 2007b). Cytoplasmic aggregates stimulate the ER stress 
signal and induce ER-stress-mediated cell death with caspase-12 activation in mouse 
cells, presumably by the accumulation of unfolded protein in the ER given the 
inhibition of retrotranslocation and ER-associated ubiquitin/proteasome degradation 
(ERAD) (Kouroku et al., 2002). Despite this evidence, the actual involvement of ER-
stress in the disease remains elusive. 
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1.4.5 Transcriptional dysregulation 
Transcriptional dysregulation has emerged as a pathogenic mechanism in HD. The 
majority of transcription factors, interacting with HTT, associate with the N-terminal 
region of the protein and these interactions are in some cases altered by the polyQ 
expansion (Steffan et al., 2000; Dunah et al., 2002). So far, the transcription factors 
found to interact with HTT include Specificity protein 1 (Sp1), CREB-binding protein 
(CBP), p53, mSin3A, nuclear receptor corepressor (NCoR), C-terminal binding protein 
(CtBP), CA150, p300/CBP associated factors (P/CAF), TATA-binding protein (TBP)-
associated factor (TAFII130), NF-Y and REST/NRSF. 
 The CRE pathway controls the expression of neuronal genes and neuronal 
survival. Deletion of CREB causes selective neurodegeneration in the hippocampus and 
striatum inducing HD-like neurological phenotypes (Mantamadiotis et al., 2002). 
Soluble mHTT interacts with both the glutamine-rich activation domain and the 
acetyltransferase domain of the co-activator CBP altering its function (Steffan et al., 
2001). The Sp1/TAFII130 pathway is also altered by soluble mHTT in a polyQ-
dependent manner, leading to transcriptional downregulation of the nerve growth 
factor and dopamine D2 receptors (Dunah et al., 2002; Li et al., 2002). mHTT binds p53 
and induces its stabilization and transcriptional activity toward proapoptotic genes 
such as Bax and Puma (Bae et al., 2005). Moreover, the abnormal interaction between 
mHTT and repressors or activators within the nucleus, (such as N-CoR (Boutell et al., 
1999), CtBP (Kegel et al., 2002), the activator CA150 (Holbert et al., 2001)), causes the 
dysregulation of transcription. Furthermore, within the nucleus, mHTT fragments form 
aggregates which sequester transcription factors, as in the case of CBP and NF-Y 
(Nucifora et al., 2001; Yamanaka et al., 2008). 
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 Transcriptional dysregulation also derives from the atypical behaviour of mHTT in 
the cytoplasm of the cells, as occurs for the REST/NRSF complex which shows reduced 
binding to mHTT as compared to the wild type. Wild-type HTT, but not the mutant 
form, promotes BDNF transcription by sequestering REST/NRSF in the cytoplasm 
thereby preventing it from forming the nuclear co-repressor complex on the neuron 
restrictive silencer element (NRSE) nuclear site and allowing gene transcription 
(Zuccato et al., 2003). 
 Consistent with transcriptional repression playing a role in the pathogenesis of 
HD, decreased acetylation and increased methylation of histones have been found in 
both experimental HD models and patients (Steffan et al., 2001; Ferrante et al., 2003; 
Ryu et al., 2006). The HD protein binds the acetyl transferase domain of different 
transcription factors such as CBP and p300/CBP Associated Factor (P/CAF), affecting 
the acetylation of histones (Steffan et al., 2001). An increase in the levels of histone 
methyl transferases, such as ESET, have been reported to affect chromatin structure 
and, ultimately, gene transcription in HD patients and mouse models (Ryu et al., 2006). 
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1.4.6 Excitotoxicity and Synaptic dysfunction  
Excitotoxicity was the first identified pathogenic mechanism to be proposed for HD 
that results in the dysfunction of neuronal interactions and circuitries at the 
corticostriatal synapse. It has been hypothesized that the excessive activation of 
glutamate receptors may be due to increased glutamate release from cortical afferents 
and a reduced uptake of glutamate by glia. Moreover, the hypersensitivity of 
postsynaptic glutamate receptors on striatal projection neurons, likely in combination 
with pathological signalling downstream of the glutamate receptor, may also 




Figure 5. Neurotransmitter systems and growth factors that are dysfunctional at the 
corticostriatal pathway. Neuronal death may depend on excitotoxicity resulting from 
increased glutamate (Glu) release from cortical neurons and increased activity of the 
glutamate receptor (NMDAR). In addition to glutamate, other neurotransmitter 
systems that control the activity of the corticostriatal synapse can contribute to render 
striatal neurons more sensitive to excitotoxic stimuli. Reproduced from (Zuccato et al., 
2010). 
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The first mechanism proposed to explain the selective vulnerability of MSNs in HD was 
excitotoxic cell death. This hypothesis is supported by a study in which MSN's express 
high levels of NMDARs, and the subsequent over-activation caused an abnormal Ca2+ 
influx, led to apoptosis (Nicholls et al., 2009). Studies have also demonstrated that the 
sensitivity of NMDAR is enhanced in HD models (Cepeda et al., 2001; Zeron et al., 
2002). This could be due to an abnormal interaction of mHTT with the post-synaptic 
density protein 95 (PSD95). PSD95 is responsible for the clustering NMDARs in lipid 
rafts at the post-synaptic membrane and changing the NMDAR subunit composition 
such that the more sensitive NR2B variant is favoured over NR2A (Fig. 6) (Milnerwood 
et al., 2010; Sun et al., 2001). 
 In addition to excitotoxicity, it’s possible to find many other process that can 
affect neurons in HD. It has been showed that mHTT can alter the availability of 
molecules involved in synaptic vesicle exocytosis (synaptobrevin-2, rabphilin 3A, 
complexin II) and recycling (PACSIN/syndapin) (Modregger et al., 2002; Morton and 
Edwardson, 2001). Moreover, the level of neurotransmitters such us dopamine, GABA, 
cannabinoid (CB1), glutamate and others are disturbed in HD mice and patients 
(Augood et al., 1996; Bibb et al., 2000; Cha et al., 1998-1999; Sun et al., 2005). 
Microarray studies have shown abnormal expression levels of genes involved in the 
mantainance of membrane potential, intracellular signalling and neuronal 
differentiation (Luthi-Carter et al., 2000). Finally, it has been shown that microtubule 
based transport is impaired in HD due the abnormal interaction of mHTT with HAP1, 
preventing it from associating with p150(Glued) an important component of 
dynein/dynactin motor complex (Gauthier et al., 2004; Gunawardena et al., 2003). 
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Figure 6. Dysfunction of Ca2+ signalling in HD. mHTT causes cytosolic and 
mitochondrial Ca2+ overload and apoptosis of MSNs in HD. mHTT perturbs Ca2+ 
signalling by enhancing NMDAR function, possibly through decreased interaction with 
the PSD95-NR1A/NR2B complex. Moreover, mHTT binds strongly to InsP3 R1, causing 
Ca2+ release through the InsP3 R1. Dopamine (DA) released from midbrain 
dopaminergic neurons stimulates D1 and D2 receptors (D1R, D2R). D1R are coupled to 
activation of adenyl cyclase, increase in cAMP levels, and activation of PKA. PKA 
potentiates glutamate-induced Ca2+ signals by facilitating the activity of NMDAR and 
InsP3 R1. D2R are coupled directly to InsP3 production and activation of InsP3 R1. 
Reproduced from Zuccato et al., 2010. 
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1.4.7 Cholesterol metabolism dysregulation 
The cholesterol synthesis pathway is another important metabolic process that is 
disrupted in HD. Cholesterol is critical to proper neuronal function. For example, 
cholesterol determines the localisation and functioning of ion channels and membrane 
receptors by acting as a modulator of membrane fluidity and an organiser of lipid rafts 
(Allen et al., 2007). Moreover, cholesterol is essential for myelination, proper neurite 
outgrowth, synaptogenesis, and the synthesis of steroid hormones (Valenza and 
Cattaneo, 2011). It is thus conceivable that a disruption of cholesterol levels could 
contribute to HD pathogenesis. 
 Several studies have already shown a decrease in expression of cholesterol 
synthesis enzymes in HD and it has been suggested that this is the result of mHTT 
disrupting the transcriptional activity of a master regulator of cholesterol synthesis 
SREBP-2 (sterol response element binding protein 2). Decrease activity of HMGCoA, (4-
hydroxy-4-methyl-glutaryl Coenzyme A reductase) involved in cholesterol synthesis, 
and a reduced brain cholesterol content, have also been observed in R6/2, YAC128, 
HdhQ111 mouse models as well as transgenic rat HD models (Valenza et al., 2005; 
2007; 2010). 
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1.5 HD models 
Since the identification of the HD causing mutation, several animal models have been 
generated to study the disease. Worm, fly and cell culture models are  helpful to study 
the basic mechanism of HD pathogenesis, but the translation of these findings to the 
human HD is limited. Placing the mutation in the context of a mammalian organism is 
essential for the proper investigation of disease mechanisms in vivo, and the validation 
of therapeutic strategies. Indeed, the most common HD mammalian models are mice, 
but rats, pigs, sheep and monkeys have also been generated. 
1.5.1 Mouse models of HD 
Various mouse models, that develop motor and cognitive deficits, as well as 
neuropathology relevant to HD, have been developed. 
These genetic models can be divided into three categories, according to how they 
were engineered. N-terminal transgenic animals carry the 5’ portion of the human 
HTT gene, which contains the mutation; whereas full-length transgenic models carry 
the full-length HTT genomic region and express the full-length HTT protein containing 
expanded polyQ repeats. The third category are knock-in models in which have been 
introduced CAG repeats of varying length into the mouse huntingtin (Htt) genomic 
locus. Models within each of these three broad categories differ in their CAG repeat 
numbers, the size and species of origin (mouse or human) of the huntingtin gene, the 
promoters that drive expression of the huntingtin gene, and, indeed, their background 
strain. Each model exhibits a somewhat different characteristic phenotype, a 
consequence of the method of their generation, and their intended purpose (Table.2).  
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Model Genetic basis Promoter Repeat length 
R6/2 Human HTT exon 1 Human HTT 200* 
N171 Human HTT exon 1,2 and part of 3 
(first 171 aa) 
Prion promoter 82 
 
BACHD Human HTT Human HTT 97 
YAC72 Human HTT Human HTT 72 
YAC128 Human HTT Human HTT 128 
HdhQ111 Mouse Htt homologue (Hdh); 
chimeric human/mouse exon 1 
Mouse Htt homologue 
(Hdh) 
111 
CAG140 Mouse Htt homologue (Hdh); 
chimeric human/mouse exon 1 
Mouse Htt homologue 
(Hdh) 
140 
HdhQ150 Mouse Htt homologue (Hdh) Mouse Htt homologue 
(Hdh) 
150 
*Average repeat length of R6/2 mice at the King’s College London colony  
 
Table 2. Summary of most commonly used HD mouse models  
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1.5.2 N-terminal transgenic fragment models 
The R6/1 (115 CAG repeats) and R6/2 (155 CAG repeats), which express mutant human 
exon 1 HTT, were the first HD transgenic lines to be produced (Mangiarini et al., 1996) 
and the R6/2 mouse has been the most extensively studied and utilized mouse model 
of HD to date. The N-terminal transgenic lines carry a small portion of the 5’ end of the 
human HTT gene, including exon 1, containing the CAG repeat region. Because these 
N-terminal containing transgenic mice were engineered via pronuclear injection, each 
transgene is integrated randomly at a unique site in the mouse genome. R6/2 mice 
express a single copy of the first exon of HTT under the control of the human HTT 
promoter that generates an exon 1 HTT transprotein with 150-200 polyQ repeats. 
These lines ha an accelerated phenotype relative to other genetically engineered lines 
(Menalled et al., 2009a) and develop behavioural abnormalities such as rotarod and 
grip strength impairments, hypo-activity and deficits in learning and memory by 8 
weeks of age (Carter et al., 1999; Lione et al.,1999). A concomitant loss of body and 
brain weight, as well as atrophy of the skeletal muscle and testis is also evident 
(Mangiarini et al., 1996). R6/2 mice also develop cytoplasmic aggregates and nuclear 
inclusions in the brain and peripheral tissues before symptom onset (Davies et al., 
1997; Li et al., 1999; Sathasivam et al., 1999). Disease progression is rapid and 
consequently R6/2 mice do not typically survive for longer than 15 weeks (at King’s 
College London colony). The N-terminal transgenic lines demonstrate that an N-
terminal mHTT fragment was sufficient to elicit HD-like neurological phenotypes in the 
mouse. 
The N171-82Q are also an N-terminal transgenic line (Schilling et al., 1999) 
expressing a 171 amino acid mHTT cDNA fragment with 82Q under the regulation of 
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the mouse prion promoter, which directs expression primarily in the brain. These mice 
develop similar behavioural and physiological abnormalities to R6/2, although onset 
and disease progression is less aggressive than in R6/2 mice. Weight loss begins 
around 2-3 months of age, rotarod impairment is evident from 4 months and end-
stage disease typically occurs at 6 months of age (Schilling et al., 1999). Cytoplasmic 
and nuclear inclusions are also formed in N171 mice, however, their distribution across 
brain regions differs from that observed in both HD patients and R6/2 mice (Schilling et 
al., 1999). This may be due to the fact that HTT transgene expression in N171 mice is 
under the control of the prion promoter. 
1.5.3 Full-length transgenic models 
The two most common HD models in which the full-length HTT transgene is carried in 
either a yeast or bacterial artificial chromosome are YAC (Yeast Artificial Chromosome) 
and BAC (Bacterial Artificial chromosome), respectively. Both YAC and BAC models 
express full length human HTT under the control of the endogenous human promoter. 
YAC HD mice are available with a polyQ length of 18, 46, 72 and 128 (Hodgson et al., 
1999; Slow et al., 2003), and BACHD mice carry 97Q (Gray et al., 2008).  
The well-studied YAC128 transgenic mouse, for example, expresses full-length human 
HTT with 128 glutamine repeats, encoded by a tract that is composed primarily of CAG 
codons but also contains 9 interspersed CAA codons (that also encode glutamine) 
(Pouladi et al., 2012). In contrast, the BAC HD mouse model expresses full-length 
human HTT containing 97 codons of a mixed CAG/CAA repeat tract (Gray et al., 2008). 
With regards to germ line and somatic instability in the YAC128 and BAC HD mouse 
models, some important considerations should be noted. First, in the YAC transgenics 
the polyglutamine stretch in exon 1 is encoded by a CAG tract that is interspersed with 
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9 CAA codons (Pouladi et al., 2012). These interspersed CAA codons appear to be 
enough to stabilize the tract to be resistant to germ line instability as the YAC128 
mouse CAG-CAA tract length does not drift over generations. Similarly, in BAC HD 
mice, the polyglutamine tract is encoded by an ordered sequence comprised of both 
CAG and CAA codons. Mixing CAG and CAA codons has been shown to confer 
resistance of the tract to expansions and contractions (Gray et al., 2008). Germ line 
and somatic instability is not seen over generational time in BAC HD mice. 
 In contrast to fragment models, transgenic full-length HD mice display a slower 
disease progression. They typically show a normal life span and also an increase of 
body weight is observed (Gray et al., 2008; Van Raansdonk et al., 2005). Both models 
develop motor impairment, activity abnormalities and cognitive deficiencies (Gray et 
al., 2008; Van Raansdonk et al., 2005). Equally, both models show a decrease in brain 
weight, and cortical and striatal degeneration evident at 12 months of age (Gray et al., 
2008; Van Raansdonk et al., 2005). Like YAC128 mice, BAC HD mice do not exibit 
reduced cortical and striatal volume until the onset of motor irregularities which are 
pronounced by 6 months of age suggesting that this is a secondary feature of disease 
(Gray et al., 2008; Slow et al., 2003). 
In YAC128 mice, by 15 months of age, intra-nuclear inclusions are visible in most brain 
regions including nucleus accumbens, ventral striatum, lateral striatum, motor cortex, 
sensory cortex and cerebellum (Bayram-Weston et al., 2012). Although disease 
progression is slower in full-length mouse models of HD, they are a useful resource to 
investigate the aspects of mHTT toxicity in the context of the full length protein.    
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1.5.4  “Knock in” HD models 
Unlike the N-terminal and full-length HD transgenic models, knock-in HD models are 
generated by homologous recombination in mouse embryonic stem cells and a 
specified number of CAGs are introduced directly into the mouse Htt. One obvious 
advantage to these models is the fidelity of the expression that results from the CAG 
repeat being carried in the context of the mouse Htt. Therefore the variability in tissue 
distribution and expression levels observed in microinjection-based HD transgenic 
models (due to transgene copy number variation and position affects resulting from 
random transgene integration) is absent. Like most HD patients, these HD knock-in 
mice can be heterozygous for one wild-type Htt allele and one CAG-expanded allele. 
Numerous HD knock-in mouse models have been described. 
 The first group generated an allelic series of knock-in mice as described by 
Wheeler and MacDonald at Massachusetts General Hospital (MGH) (Wheeler et al., 
1999). These knock-in mice have a human exon 1 sequence engineered with repeats of 
18, 48, 78, 90 and 109 CAGs targeting one allele of mouse Htt. The most well described 
mouse in this knock-in series is the HdhQ111 mouse (111 glutamines encoded by a 
(CAG)
109
CAACAG sequence) (Wheeler et al., 2000). 
 The second group is an allelic series of knock-in mice generated and created by 
Lin and Detloff at the University of Alabama, Birmingham (UAB) (Lin et al., 2001). 
These knock-in mice have expanded CAG tract with 50, 100, 150, 200, 250, 315 and 
365 CAGs in the mouse Htt exon 1 sequence (Heng et al., 2010b; Lin et al., 2001; 
Sathasivam et al., 2013). The 150 CAG-repeat line, denoted HdhQ150, is the most well 
studied of this series. Unlike the MGH series, these mice contain no human sequence; 
100% of the mHTT expressed in these mice is derived from the mouse Htt gene.  
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 The third group developed by Zeitlin are knock-in mouse models of HD with a 
chimeric mouse/human exon 1 containing 140 CAG repeats inserted in the murine Htt. 
They are heterozygous for an HTT allele with an expanded CAG repeat size of 71, 94 
and 140 in the human HTT exon 1 sequence (Levine et al., 1999; Menalled et al., 2003). 
Consequently, both the MGH and Zeitlin knock-in mice encode the human exon 1 
sequence in the context of a full length mouse Htt locus while the Detloff knock-in 
mice are entirely mouse Htt sequence. 
 As for the transgenic full length HTT mice, the knock-in mice exhibit a slow 
disease progression. However, changes in certain behaviours such as activity and 
rearing can be detected as early as 1 month of age in the CAG140 mice, though these 
mice do not display any overt pathological signs such as weight loss, tremor or clasping 
at 1 year of age (Menalled et al., 2003). HdhQ150 mice do not display physiological 
abnormality until 12 months of age with rotarod impairment only becoming 
pronounced by 18 months of age (Woodman et al., 2007). Nevertheless, these mice 
form cytoplasmic and nuclear aggregates by 6 months of age and by 21-22 months 
their pattern of aggregation, both the CNS and peripheral tissues, is as widespread as 
that of R6/2 mice at 12 weeks of age (Woodman et al., 2007; Moffitt et al., 2009). 
Aggregation is also a feature of disease in HdhQ111 and CAG140 mice, where diffuse 
nuclear staining can be observed by 1-2 months of age, and nuclear inclusions appear 
by 6 (CAG140) and 10 months of age (HdhQ111) (Menalled et al., 2003; Wheeler et al., 
2000). 
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1.5.5 HD mouse models: conflicts and similarities  
Mouse models of HD share many features but at the same time they show many 
discrepancies. For example, while R6/2 and HdhQ150 mice develop mHTT inclusions in 
the brain prior to behavioural abnormalities, this is not the case in YAC and BAC mice 
where smaller aggregates are more commonly found throughout neuronal nuclei and 
the neuropil (Woodman et al., 2007; Moffitt et al., 2009; Gray et al., 2008; Slow et al., 
2003). The main difference between HD mouse models is the rate of the disease 
progression. N-terminal HTT fragments mouse models generally develop symptoms 
earlier than mice expressing full length HTT (Crook and Housman, 2001)  (Fig.7).  
The rapid disease progression of R6/2 mice allows for efficient preclinical compound 
screening, but the full-length or knock-in models, with longer pre-manifest stage could 
be more useful for elucidation of subtle molecular changes that occur before symptom 
onset in an adult organism. Also, some molecular events and their role in HD 
pathology, such as proteolytic cleavage, cannot be examined without the context of 
the full length mutant protein. If, indeed, toxicity is caused by N-terminal fragments, 
fragment models could be used to study the sequence of pathological events and 
applicability of therapeutic strategy downstream of HTT cleavage. 
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Figure 7. Timeline of Behavioral and Neuropathological Symptoms in HD mouse 
models. Transgenic fragment (R6/2 and N171) models develop motor dysfunction and 
molecular pathologies earlier than transgenic full length (BACHD, YAC72 and 128) and 
knock-in (HdhQ111, CAG140 and HdhQ150) mice. (Modified from Crook and Housman, 
2011) 
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1.6 Histone deacetylases classification and mechanism of reaction 
The HDACs can be divided into four classes depending on their sequence homology to 
yeast enzymes. Class I includes HDAC1, HDAC2, HDAC3 and HDAC8, which are 
homologous to the yeast enzyme Rpd3 (De Ruijter et al., 2003). Class IIa includes 
HDAC4, HDAC5, HDAC7 and HDAC9, whereas class IIb contains HDAC6 and HDAC10 
(Fig.8) (De Ruijter et al., 2003). All members of class II share most homology with the 




Figure 8. Classification of classes I, II, and IV HDACs by structure and intracellular 
localization. (Modified from Bolden et al., 2006) 
Chapter 1                                                                                      Introduct ion                                                                                               




Sirtuins form the class III deacetylases which contain 7 enzymes that are all similar to 
the yeast Sir2, thus named SIRT1 through SIRT7 (Fig.9) (Finkel et al., 2009). 
 Class IV’s only member is HDAC11, which, due to insufficient sequence 
homology, cannot be included in any other class (Gao et al., 2002). 
The class I, II and IV HDACs have different mechanism of action as compared to the 
class III deacetylases. HDACs 1 through 11 are all zinc-dependent enzymes and share 
the same reaction mechanism. The reaction needs  Zn2+  ion coordinated by histidine 
and aspartate residues in a highly conserved catalytic core. Deacetylation occurs by the 
activation of a water molecule by the zinc cation, coupled to the histidine-aspartate 
charge relay system, within the active site (Finnin et al., 1999). The sirtuin reaction 
mechanism is NAD+ (nicotinamide adenine dinucleotide) dependent and proceeds 
through the formation of an oxocarbenium-like transition species and release of 
nicotinamide (NAM). Upon completion, apart from the deacetylated substrate, 2’-O-
acetyl ADP ribose is released (Liang et al., 2010). 
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Figure 9. Schematic representation of human sirtuins family members 1–7. NAD-
dependent catalytic domain (gold) (NAD-binding pocket), zinc-binding domain (black), 
and their intracellular localization. Reproduced from Rajendran et al., 2011. 
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1.6.1 Expression and functions of HDAC enzymes 
Class I HDACs are expressed in a variety of tissues suggesting that they have a general 
regulatory function in transcriptional control (Johnstone et al., 2002). HDAC1 and 
HDAC2 possess high sequence homology (De Ruijter et al., 2003). Located exclusively 
in the nucleus, they generally form part of multi-protein transcription modulating 
complexes such as Sin3, NuRD (nuclear remodelling deacetylase) or Co-REST (co-
repressor of rest) (Ahringer et al., 2000; Humphrey et al., 2001). HDAC3 is the only 
class I member that, in addition to a nuclear localisation signal (NLS), also possesses a 
nuclear export signal (NES) (Yang et al., 2002). Consistent with this, HDAC3 has been 
detected in both the nucleus and the cytoplasm where it is believed to localise to the 
plasma membrane (Emiliani et al., 1998). 
 HDAC4, HDAC5, HDAC7 and HDAC9 have their catalytic domain at the C-terminus 
and an NLS at the N-terminus (Yang and Seto, 2008). However, the N-terminus also has 
conserved domains for binding the C-terminal binding protein (CtBP), myogenic 
enhancer factor (MEF2) and 14-3-3 proteins (Yang and Gregoire, 2005). MEF2 is 
essential for muscular differentiation and is inhibited through binding class IIa HDACs 
(Verdin et al., 2003). This association is disrupted by CaMK phosphorylation and the 
export of HDACs to the cytoplasm via association with 14-3-3 proteins (McKinsey et al., 
2000). HDAC4, HDAC5 and HDAC7 have also been shown to interact with HDAC3 with 
the N-CoR/SMRT (nuclear co-repressor/silencing mediator for retinoic acid and thyroid 
hormone receptors) repressive complex (Fischle et al., 2002). In fact, data suggest that 
HDAC4, HDAC5 or HDAC7 may not possess histone deacetylase activity and therefore 
associate with HDAC3 to achieve transcriptional repression (Fischle et al., 2002). 
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HDAC6 and HDAC10 are unique in that they have a duplication of the catalytic domain, 
although the duplicated domain appears to be functional in HDAC6 only (Yang and 
Seto, 2008). It has been shown that HDAC6 is involved in α-tubulin acetylation 
throughout the brain (Bobrowska et al., 2011). HDAC10, as well as the class IV 
HDAC11, have only recently been identified and little is known of these two enzymes. 
HDAC10 has so far been implicated in DNA homologous recombination and 3’ pre-
mRNA processing and appears to be vertebrate specific, whereas HDAC11 is conserved 
through invertebrates and plants but more investigation is needed to pinpoint its 
cellular functions (Gao et al., 2002; Kotian et al., 2011; Shimazu et al., 2007; Yang and 
Seto., 2008). 
 The sirtuins can be found in the nucleus (SIRT1, SIRT6 and SIRT7), the 
mitochondrion (SIRT3-5) and in the cytoplasm (SIRT2) (Finkel et al., 2009). So far, SIRT1 
has been most extensively studied, due to its highest homology with the yeast Sir2 
enzyme and it has been implicated in mediating lifespan extension (Kaeberlein et al., 
1999; Tissenbaum and Guarente, 2001). It has also been implicated in the DNA damage 
response, oxidative stress and heat shock response, cellular differentiation and 
metabolism (Wang et al., 2008c; Westerheide et al., 2009; Yuan et al., 2007). SIRT2 is 
the only predominantly cytosolic sirtuin. Like HDAC6, SIRT2 has been proposed to be 
an α-tubulin deacetylase. While knocking-out HDAC6 in mice led to an increase in α-
tubulin acetylation, this was not the case when SIRT2 was knocked-out (Bobrowska et 
al., 2011). Mitochondrial sirtuins have been shown to function as regulators of energy 
production through the concerted action of deacetylation and ADP-ribosylation. SIRT3 
can deacetylate acetyl-CoA synthetase 2, resulting in an increased production of 
acetyl-CoA, an intermediate in the Krebs cycle, fatty acid metabolism, and cholesterol 
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synthesis (Hallows et al., 2006). SIRT4 does not seem to possess deacetylase activity, 
but instead uses NAD+ to ADP-ribosylate glutamate dehydrogenase, inactivating it in 
liver and pancreatic β-cells, and regulating gluconeogenesis and insulin secretion in 
response to glutamine (Haigis et al., 2006).  Little is known about SIRT5, although it has 
been recently shown to deacetylate carbamoyl phosphate synthetase 1, thereby 
activating it and inducing increased urea production in the liver (Nakagawa et al., 
2009). As SIRT5 mRNA levels are upregulated during fasting, its action on the urea 
cycle could be protective by increasing the conversion of increased ammonia 
generated in the process to non-toxic urea (Ogura et al., 2010). SIRT6 is another sirtuin 
without deacetylase but with ADP-ribosylase activity. The substrates are still unknown, 
but studies from SIRT6-deficient mice indicate a role for this protein in base-excision 
repair (Mostoslavsky et al., 2006).  SIRT7 is a nucleolar enzyme expressed mainly in 
proliferative tissues such as liver, spleen and testes, with low expression in heart, brain 
or muscle (Ford et al., 2006). SIRT7 can associate with Pol I and its over-expression 
increased transcription of rRNA, suggesting that SIRT7 could promote growth by 
driving ribosome biosynthesis in proliferating cells (Ford et al., 2006).  
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1.7 SIRT1 as therapeutic target in HD 
Several studies have shown that SIRT1 can delay aging and promote longevity through 
regulating the activity of proteins such as p53, FOXO and Ku70, which are involved in 
apoptotic processes or cellular repair mechanisms (Pasinetti et al., 2010). Moreover, 
there is evidence to demonstrate that caloric restriction can improve motor 
impairments and extend survival in HD mouse models (Duan et al., 2003), indicating 
that pathways related to energy metabolism can modify disease. Caloric restriction 
increases mitochondrial biogenesis and the production of NO (Nitric Oxide) that can 
activate the Sirt1 gene (Nisoli et al., 2005; Guarente et al ., 2006). Moreover, SIRT1 has 
been suggested to mediate some beneficial effects of caloric restriction (Canto and 
Auwerx et al, 2009; Wakeling et al., 2009; Shimokawa and Trindade et al, 2010; 
Chalkiadaki and Guarente et al, 2012). The first report demonstrating a link between 
SIRT1 and HD came from studies by Parker (2005), where overexpression of Sir2.1 
(homolog of SIRT1 in C. elegans) rescued neuronal dysfunction induced by mutant 
polyglutamine in Caenorhabditis elegans. In contrast to the neuroprotective effect of 
Sir2.1 in C. elegans, Pallos (2008) reported that 50% reduction of Sir2 extended survival 
and preserved photoreceptor-containing neurons in flies expressing mHTT. 
Interestingly, in the fly model system, overexpression of Sir2 does not reduce the 
lethality or the level of neuronal degeneration caused by mHTT. Studies in both C. 
elegans and Drosophila suggest that complete loss of Sir2 is deleterious in the worm 
(Parker et al., 2005) and is deleterious compared with heterozygous loss in mHTT-
challenged flies (Pallos et al., 2008). Although heterozygous loss of Sir2 is protective in 
flies, heterozygous loss of Sir2 in worms was not examined.  
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Due to these contradictory results, further investigations into the role of SIRT1 in 
mammalian systems were needed. Indeed, two independent studies from Duan’s 
(Jiang et al., 2011) and Krainc’s groups (Jeong et al.,2011) demonstrated that 
modulating the levels of SIRT1 had some therapeutic benefit in three different HD 
mouse models. This supports the notion that SIRT1 has beneficial effects in HD mouse 
models. It is possible to explain the contradictory results on the effects of SIRT1 in 
models of HD as SIRT1 has numerous targets (Fig. 54), and different models of HD 
display different phenotypes by activating various targets and mechanisms. Therefore, 
it is not surprising to observe contradictory data, especially in different models and 
species. 
  
Chapter 1                                                                                      Introduct ion                                                                                               




1.7.1 SIRT1 protein and its proposed function 
The SIRT1 gene spans about 34 kb including nine exons. Human SIRT1 encodes a 747 
amino acid protein with a nuclear localization signal (NLS) at the N-terminus (aa 41-46) 
and a sirtuin homology domain at the centre (aa 261-447); this domain is a conserved 
catalytic domain for deacetylation. SIRT1 is predominately in the nucleus. In addition 
to possessing two nuclear localization signals, it also contains two nuclear export 







Figure 10. SIRT1 functional domains. Human SIRT1 has two consensus nuclear 
localization signals (NLS) and two nuclear export signals (NES), one of which is nested 
in the catalytic domain. SIRT1 can be phosphorylated (P) by JNK1, CK2, PKA, CDK1, and 
DRYKs. (Modified from Thomas G. Brock, Cayman chemical). 
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As one of the most conserved mammalian sirtuins, SIRT1 plays essential roles in many 
biological processes. Nature has evolved a variety of strategies to modulate tightly the 
activity of SIRT1 in response to different stimuli. In particular, as an enzyme, substrate 
availability, PTMs, interacting protein partners, or small molecule activators or 
repressors can directly regulate the activity of SIRT1.  
 Like all enzymes, the catalytic activity of SIRT1 is dependent on its substrates: 
acetylated proteins and NAD+. The SIRT1 enzymatic reaction catalyzes the 
deacetylation of protein targets by hydrolyzing NAD+ and transferring the lysine-bound 
acetyl group to the 2' -OH position of ADP-ribose, thereby generating a protein with a 
deacetylated lysine residue, 2'-O-acetyl-ADP-ribose, and nicotinamide. The discovery 
that SIRT1 exclusively utilizes NAD+ as a co-substrate raises the possibility that its 
activity is also intrinsically linked to the energy status of the cell. In this scenario, a low-
energy status would increase SIRT1 activity by increasing the levels of NAD+, whereas a 
high-energy status would decrease SIRT1 activity by decreasing the levels of NAD+.  
 It has been shown that SIRT1 function is also regulated by post-translational 
modifications and the main PTM to control its function is the phosphorylation. For 
example, the MAP kinase JNK1, activated by cellular stresses, phosphorylates SIRT1 on 
three residues promoting nuclear accumulation of SIRT1 and increasing its 
deacetylation activity. In mice, persistent JNK1 activation and phosphorylation of SIRT1 
at S46 is followed by ubiquitination and proteasomal degradation of SIRT1 (Nasrin et 
al., 2009). Casein kinase 2 (CK2) can, like JNK1, be activated by stress. Ionizing radiation 
induces CK2-mediated phosphorylation of SIRT1 on multiple sites. This 
phosphorylation of SIRT1 increases deacetylation of P53 and protects against 
apoptosis following DNA damage (Mahlknecht et al, 2009). Phosphorylation of SIRT1 
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by PKA increases the rate of deacetylation of PGC-1α and augments fatty acid 
oxidation (Gerhart-Hines et al., 2011). Phosphorylation of SIRT1 by cyclin B/CDK1 
appears to be required for normal cell cycle progression (Sasaki  et al., 2008). Tyrosine 
phosphorylation-regulated kinases DYRK1A and DYRK3 target SIRT1, which increases 
deacetylation of P53 and protects against DNA damage-induced cell death (Guo et al., 
2009).  
 SIRT1 performs several functions, it is involved in obesity-associated-metabolic 
diseases, cancer, adipose tissue, aging, cellular senescence, cardiac aging and stress, 
neurodegeneration, inflammatory signalling in response to environmental stress, 
development and placental cell survival (Luo et al., 2001; Stunkel et al., 2007; Chen et 
al 2008). One of the most important functions of SIRT1 is to protect the cell against 
stress. Indeed, SIRT1 up-regulates stress-protective pathways by the deacetylation of 
FOXO transcription factors, leading to increased transcription of GADD45 (DNA repair) 
and MnSOD (reactive oxygen detoxiﬁcation). SIRT1 concomitantly down-regulates 
FOXO transcription of the proapoptotic factors FAS (Fatty acid synthase) and Bcl-2 
interacting mediator of cell death (BIM). Interestingly, under stress conditions SIRT1 
also interacts with P53 and deacetylates its C-terminal regulatory domain (Vaziri et al., 
2001). This activity downregulates P53 transcriptional effects, which is consistent with  
the evidence indicating that the deacetylation of the C-terminal domain of P53 
weakens DNA binding activity (Vaziri et al., 2001). Importantly, Sirt1KO animals have 
hyperacetylated P53, which suggests that SIRT1 typically regulates P53 acetylation 
levels in wild-type animals (Cheng H. et al.,2003). Several other SIRT1 protein 
substrates involved in cell stress response signalling have been identiﬁed, including 
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ku70, a proapoptotic factor which is down-regulated by SIRT1 deacetylation, and the 
transcriptional coactivator PGC1- α (Rodgers JT et al., 2005).  
1.7.2 DBC1 (Deleted in breast cancer-1) is a negative regulator of SIRT1 
Several transient protein–protein interactions also play key roles in the regulation of 
SIRT1 activity. DBC1 (Deleted in breast cancer-1), originally identified as a gene (8p21) 
homozygously deleted in breast cancer and some other tumors, has been shown to 
regulate SIRT1 activity. DBC1 is a large protein, found both in the nucleus and 
cytoplasm, with multiple functions in the cell. It can promote p53-mediated apoptosis 
by binding to, and inhibiting, the deacetylase activity of SIRT1, resulting in increased 
p53 acetylation levels and activity (Zhao et al., 2008). DBC1 may be an important 
regulator of heterochromatin formation as it binds SUV39H1 and inhibits its histone 
methyltransferase activity (Li et al., 2009). Caspase-dependent processing activates the 
pro-apoptotic activity of DBC1 during tumor necrosis factor-α (TNF-α)- mediated cell 
death signalling (Sundararajan et al., 2005). 
DBC1 is composed of different domains including a nuclear localization signal, an N-
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Ja-Eun Kim and colleagues have shown that the DBC1 leucine zipper domain (243-264) 
is required for the interaction with the catalytic domain of SIRT1. As consequence, 
DBC1 forms a stable complex with SIRT1, thus inhibiting SIRT1 activity in vitro and in 
vivo (Kim et al., 2008). They also showed that the downregulation of DBC1 expression 
potentiates SIRT1-dependent inhibition of the apoptosis induced by genotoxic stress 
(Kim et al.,2008).  
 It has been shown that SIRT1 adopts a hook conformation.  When SIRT1 needs to 
be activated, its c-terminal region, named ESA, bends like a hook interacting with the 
catalytic domain. This interaction keeps SIRT1 activated and increases the affinity for 
its substrates. Moreover the binding site for ESA in the catalytic domain is also the 
interaction site of DBC1 (Kim et al., 2008). Two CK2 phosphorylation sites seem to be 
important in controlling the catalytic activity as they are located in the ESA SIRT1 
region. It is, therefore, possible that these phosphorylation sites modulate the 
interaction of the C-terminal region with the catalytic domain. This might affect the 
catalytic region and substrate binding through an allosteric mechanism.  Additionally it 
might affect the binding of DCB1, which is a SIRT1 inhibitor (Fig. 12). 
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Figure 12. The ESA motif competes with DBC1 binding, a negative regulator of SIRT1. 
Enhanced interaction of ESA with the core domain of SIRT1  in response to CK2 
phosphorylation would prevent binding of DBC1 and thus abrogate its inhibitory effect. 
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It has been observed that PKA activation leads to a rapid, and transient activation of 
SIRT1 that is DBC1-dependent (Carlos Escande et al., 2012). In fact, an increase in 
cAMP/PKA activity results in the dissociation of SIRT1 and DBC1 in an AMPK-
dependent manner. Pharmacological AMPK activation leads to SIRT1 activation by a 
DBC1-dependent mechanism. Indeed, Escande and Colleagues found that AMPK 
activators promote SIRT1-DBC1 dissociation in cells, resulting in an increase in SIRT1 





Figure 13. SIRT1 regulation by PKA and AMPK. SIRT1–DBC1 interaction is modulated 
by input from the cAMP–PKA (protein kinase A) and AMPK signalling pathways. Both 
these pathways activate SIRT1 by modulating the SIRT1–DBC1 interaction. Reproduced 
from Escande et al., 2012. 
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1.7.3 SIRT1 is an anti-apoptotic protein 
SIRT1 plays a vital role in the regulation of metabolism, stress responses, genome 
stability, and ultimately aging. Moreover, much attention has focused on its anti-
apoptotic function. In particular, SIRT1 is able to exert the anti-apoptotic function 
through the deacetylation and inactivation of P53 (Yi et al., 2010). Pathological 
conditions such as cancer, neurodegeneration, ischemia, cholestasis, and 
atherosclerosis are all strongly associated with deregulated levels of apoptosis in which 
P53 dysfunction has a prominent role. 
A wide variety of cellular stress signalling pathways engage the P53 network, resulting 
in the activation of the P53 protein. The DNA damage, the aberrant proliferative 
signalling, hypoxia are all involved in the activation of P53. As consequence, several 
proteins can be involved in the activation of this apoptotic factor. 
One of the most dramatic effects of P53 activation is the induction of apoptosis. In the 
mitochondrial pathway, death stimuli target mitochondria either directly or through 
transduction by proapoptotic members of the Bcl-2 family, such as Bax and Bak. The 
mitochondria then release apoptogenic proteins, ultimately leading to caspases 
activation and apoptosis (Vousden et al., 2009). Cells committed to die via P53-
dependent apoptosis typically follow the mitochondrial pathway. Furthermore, most 
evidence suggests that the key contribution of P53 to apoptosis is primarily dependent 
on transcriptional activity. P53 has the ability to activate transcription of various 
proapoptotic genes, including those encoding members of the Bcl-2 family, such as the 
BH-3 only proteins Bax, Noxa, and Puma (Jeffers et al., 2003) (Fig. 14). 
In addition to mitochondrial-targeted P53 actions, an alternative cytosolic P53 death 
pathway has been reported. It directly activates cytosolic Bax. After stress, nuclear P53 
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induces transcription of PUMA, which in turn, liberates P53 from an inactive pre-
existing soluble p53-Bcl-XL complex, via binding to Bcl-XL. The cytosolic P53 then 
induces homo-oligomerization of Bax, followed by Bax mitochondrial translocation 




Figure 14. Cytosolic and mitochondrial P53 apoptotic pathways. (Reproduced by 
Amaral et al., 2010) 
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1.7.4 Aim of this work 
The therapeutic potential of SIRT1 for neurodegenerative disease has been tested in 
several models of HD. Recent evidence suggests that this enzyme participates in 
neuronal protection and prevents neurodegenerative diseases in mouse models by 
modulating deacetylation activities through a variety of substrates including P53 (Kim 
et al.,2007) and HSF1 (Donmez et al., 2010). However, the exact nature of normal 
SIRT1 function in the mammalian brain has not been ascertained.  
 The role of SIRT1 in HD has been previously studied in mouse models. Increased 
expression of Sirt1 was found to attenuate neurodegeneration and improve motor 
function in N171-82Q and BACHD mice (Jiang et al., 2011). Although a second study 
reported that overexpression of Sirt1 attenuates brain atrophy and reduces 
aggregation of mHTT in R6/2 mice (Jeong et al., 2011). Based on these findings, a mis-
regulation of SIRT1 function could have important implications in the development and 
progression of HD.  
In this work, we explore the impact of HD pathology on SIRT1 function in the brain. We 
provide evidence for a considerable down-regulation of SIRT1 activity in the brain of 
R6/2 and HdhQ150 mice.  
Moreover, we tried to understand more about the mechanism that regulates SIRT1 
activity in the brain. We show a striatum-specific age-dependent regulatory 
mechanism of SIRT1 activity in WT mice and we assumed the existence of a link 
between SIRT1 activity and SIRT1 phosphorylation status in physiological conditions. 
Since a specific activator of SIRT1 is not available yet, to rescue the deficit of SIRT1 
activity in HD mouse models we used a genetic approach to reduce Dbc1 expression in 
R6/2 mice to restore SIRT1 activity and subsequently improve the disease phenotype. 
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We have therefore crossed R6/2 transgenic mice with mice in which DBC1 has been 
reduced, or ablated, to evaluate whether the increase of in SIRT1 activity had a 
beneficial impact on disease progression.  
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Chapter 2 MATERIALS AND METHODS 
2.1 Materials 
2.1.1 Commercial Kits 
Amersham ECLTM Plus Wester Blotting detection Kit (GE Healthcare)  
Bicinchocinic acid (BCA) Assay (Thermo Scientific) 
DNase I set (Qiagen) 
QIAzol Lysis reagent (Qiagen) 
RNeasy Mini Kit (Qiagen)  
SIRT1 Fluor-de-lys activity assay (Enzo Life Sciences) 
2.1.2 Equipment 
7650 accelerating rotarod (Ugo BAsile) 
96-well transparent polypropylene PCR plates for genotyping (Bio-Rad) 
96-well white polypropylene PCR plates (Bio-Rad) 
AM1053 activity cages (Linton Instruments) 
Analytical balance (Fisher) 
Capex 8C, Charles Austen Vacuum and pressure Laboratory Pump X37-950 
CFX96 Real-time system thermocycler (Bio-Rad) 
Chromo-4 thermo cycler (Bio-Rad) 
Confocal microscope (Leica TCS SP2) 
DNA Engine Dyad thermocycler (Bio-Rad) 
Fast-Prep Ribolyser (MP Biomedicals) 
GD40/50 vacuum gel drier (Life technologies) 
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Gel-Doc EQ UV-transilluminator (Bio-Rad) 
Grip Strength  meter (San Diego Instruments) 
GS-800 Calibrated Densitometer (Bio-Rad) 
Heraeus Fresco 17 Centrifuge (Thermo Scientific) 
Heraeus Pico 17 Centrifuge (Thermo Scientific) 
L8-80M ultracentrifuge (Beckman Coulter) 
Lysing matrix-D tubes (MP Biomedicals) 
Nanodrop spectrophotometer (Thermo Scientific) 
Omega plate reader (BMG Labtech) 
OTC cryostat (Bright Instruments) 
Polypropylene tubes (1.5 ml) (Eppendorf) 
Protean Minigel Western Blotting system (Bio-Rad) 
PT 1200 homogenizer (Polytron) 
Semi-transparent shoebox mouse cage (Techniplast Limited) 
Shaker IKA KS 260 basic  
Sorvall Legend RT Refrigerated Benchtop Centrifuge  
Transilluminator TL-33 (UVP) 
Transparent activity box (367x207x140 cm) (Techniplast Limited) 
UBD2 heating block (Grant instrument) 
Ultrasonic bath XB3 (Grant instrument) 
Vibra-Cell sonicator (Sonics and Materials incorporated) 
X-ray film developer (Xenograps) 
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2’-deoxynucleotide triphosphates (dNTPs) (Invitogen) 
2-mercaptoethanol (Sigma) 
4-(2-Hydroxyethyl)piperazine-1-ethanesulfonic acid sodium salt (HEPES) (Sigma) 
Ammonium persulfate ((NH4)2S2O8)) (Sigma) 
Bovine serum albumin (BSA) (Sigma) 
Bromophenol blue (Sigma) 
Chloroform (Sigma) 
Complete protease inhibitor tablet (Roche) 
Dimethyl sulphoxide (DMSO) (Sigma) 
Dithiothreitol (DTT) (Sigma) 
Ethanol (VWR) 
Ethidium bromide (Sigma) 




GoTaq-Flexi DNA Polymerase (Promega) 
Hyperfilm ECL (Amersham) 
Igepal-CA630 (NP-40) (Sigma) 
Lambda Hind III / phiX Hae III Marker (New England Biolabs) 
Magnesium chloride (MgCl2) (Sigma) 
Methanol (VWR) 
MMLV-RT 1st standard buffer (5x) (Invitrogen) 
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Moloney murine leukemia virus reverse transcriptase (MMLV-RT) (Invitrogen) 
Nicotinamide (NAM) (Sigma) 
Non-fat dry milk powder (Marvel) 
Phenyl methyl sulphonyl fluoride (PMSF) (Fluka) 
Phosphate buffer saline (PBS) tablets (Sigma) 
Precision mastermix (2x) (Primer Design) 
Proteinase K (Fermentas) 
Protogel (GeneFlow) 
Protogel resolving buffer (GeneFlow) 
Protogel stacking buffer (GeneFlow) 
Protran nitrocellulose membrane (0.2 µm pore) (Bio-Rad) 
RNasin (Promega) 
Rodent breeding chow (Special Diet Services) 
SDS-PAGE running buffer (10x) (GeneFlow) 
Sodium bicarbonate (NaHCO3) 
Sodium carbonate (NaCO3) 
Sodium chloride (NaCl) (VWR) 
Sodium deoxycholate (Sigma) 
Sodium dodecyl sulphate (SDS) (Sigma) 
Spectra pre-stained protein marker (Fermentas) 
Sucrose (VWR) 
Taq DNA Polymerase from Thermus aquaticus (Sigma) 
Tetra methyl ethylene diamine (TEMED) (Sigma) 
Trichostatin A (TSA) (Sigma) 
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Tris base (Sigma) 
Triton-X100 (Sigma) 
Tween-20 (Sigma) 
Ultra-pure agarose (Invitrogen) 
Ultra-pure water (Sigma) 
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Antibody Catalogue # Source Dilution 
DBC1 A300-432A Bethyl lab. 1:1000 (WB) 
 1:100 (IHC) 
SIRT1 ab12193 Abcam 1:1000 (WB) 
1:100 (IHC) 
P53 sc-6243 Santa cruz 1:100 (IHC) 
AcP53 ab122899 Abcam 1:50 (IHC) 
MpM2 05-368 Millipore 1:1000 (WB) 
HTT MAB5374(EM48) Millipore 1:100 (IHC) 
HTT MAB2166 Millipore 1:2500 (WB) 
AMPKα1 A300-507A Bethyl lab. 1:500 (WB) 
AMPKα1 ab32047 Abcam 1:10 (IP) 
β-actin sc-47778 Santa-Cruz 1: 10000 (WB) 
ATP5B ab14730 Abcam  1:15000 (WB) 
-tubulin T9026 Sigma 1:30000 (WB) 
Histone H3 ab1791 Abcam 1:30000 (WB) 
 
Table 3. Summary of the application and dilution of all antibodies. WB: western 
blotting; IP: Immunoprecipitation;  IHC Immunohistochemistry.  
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2.1.5 Genotyping, sequencing and real time quantitative PCR primers and probes. 
Name Application 5'-3' sequence 
Dbc1 forward RT-qPCR GTACCAGAAGGCAGCTGGAG 
Dbc1 reverse RT-qPCR TGAAGAGGCTGAGCACAGAA 
Dbc1 probe RT-qPCR AGGCTACCCCTGCTGTGGCTCCCA 
HTT exon 1 forward RT-qPCR GAGTCCCTCAAGTCCTTCCAGCA 
HTT exon 1 reverse RT-qPCR GCCCAAACTCACGGTCGGT 
HTT exon 1 probe RT-qPCR CAGCTCCCTGTCCCGGCGG 
Hdac1 forward RT-qPCR TCTGAATACAGCAAGCAGATGCA 
Hdac1 reverse RT-qPCR ACAGAACTCAAACAAGCCATCAAAC 
Hdac1 probe RT-qPCR CGGTCCACACCCGCCACCAG 
Hdac2 forward RT-qPCR AGAAGATTGTCCGGTGTTTGATG 
Hdac2 reverse RT-qPCR CACAGCCCCAGCAACTGAA 
Hdac2 probe RT-qPCR TTGAGTTTTGTCAGCTCTCCACGGGTG 
Hdac3 forward RT-qPCR TCAGCCCCACCAATATGCA 
Hdac3 reverse RT-qPCR GAACTCGAAAAGTCCTGGAAACA 
Hdac3 probe RT-qPCR AGACCTAATGGAACAAAAGTGGCTGTGCTG 
Hdac4 forward RT-qPCR CTGGCATCCCTGTGTCATTTG 
Hdac4 reverse RT-qPCR ACACAAGACCTGTGGTGAACCTT 
Hdac4 probe RT-qPCR CTGCCACCTTCCCCATGTCAGTCC 
Hdac5 forward RT-qPCR CCAGAGCCGGCATAACT 
Hdac5 reverse RT-qPCR GCAGGATTTCCAAGATGGTT 
Hdac5 probe RT-qPCR TTCCACCAGGTGAGAAGAGTGATGACCAT 
Hdac6 forward RT-qPCR GGAGACAACCCAGTA CATGAATGAA 
Hdac6 reverse RT-qPCR CGGAGGACAGAGCCTGTAG 
Hdac6 probe RT-qPCR TATCTGCATCCGAACCTCATATTCCTGTGCCTG 
Hdac7 forward RT-qPCR CCCACCTGTCAGACCCAAGT 
Hdac7 reverse RT-qPCR AGTCATAGACCAGCCCTGTAGCA 
Hdac7 probe RT-qPCR CTCAACAGCTCAGAGACA 
Hdac8 forward RT-qPCR GGCCCATCCATCCCTGTAG 
Hdac8 reverse RT-qPCR TTTAGATCGCCGGAGACAGTTT 
Hdac8 probe RT-qPCR TGGACGAGGGACCAGG 
Hdac9 forward RT-qPCR TGGCAGAATCCTCGGTCAGT 
Hdac9 reverse RT-qPCR CCCAGCAGGGCCATTGT 
Hdac9 probe RT-qPCR TCTCCAGGGTCAGGTCCCAGTTCACC 
Hdac10 forward RT-qPCR CCGCTATGAGCATGGAAGCT 
Hdac10 reverse RT-qPCR CAACTGCATCTGCATCAGACTCT 
Hdac10 probe RT-qPCR CTGGCCGTTTCTC 
Hdac11 forward RT-qPCR TGGGCATGAGCGAGACTTC 
Hdac11 reverse RT-qPCR GCGGTTGTAAACATCCATGATG 
Hdac11 probe RT-qPCR TGGGTGACAAGCGAG 
Sirt1 forward RT-qPCR TGTTGGTTGACTTCATCTTCCTT 
Sirt1 reverse RT-qPCR TCCAATGGCTTTTGAAAACTTTA 
Sirt1 probe RT-qPCR TTCATTTGTATGATACATTCGTATGTATG 
Sirt2 forward RT-qPCR TCCTGCAGAAAAGAATACACGAT 
Sirt2 reverse RT-qPCR CGATATCAGGCTTTACCACACTC 
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Table 4. Summary of in house designed primer and probe sequences for qPCR. 
Primers and probe mixes for Sirt4, Sirt6 and cholesterol pathway genes were 
purchased from Primer Design. All RT-qPCR probes were labelled 5' with FAM and 3' 
with TAMRA. RT-qPCR real time-quantitative PCR; HTT exon 1 (R6/2 transgene).  
  
Sirt2 probe RT-qPCR AGAGAAGATCTTCTCAGAAGCAACTCC 
Sirt3 forward RT-qPCR ACAAGAACTGCTGGATCTTATGC 
Sirt3 reverse RT-qPCR TCTTGCTGGACATAGGATGATCT 
Sirt3 probe RT-qPCR ACGTGGCAAGCTG GATGGACAGGA 
Sirt4  RT-qPCR Assay was purchased from Primer Design 
Sirt5 forward RT-qPCR CAGAGGCGCTGGAGGTTACTGGAG 
Sirt5 reverse RT-qPCR CCGGGCTTCACACTGGGCAATGGC 
Sirt5 probe RT-qPCR AGGCTCAGGACCTGGCAACCCCTCAG 
Sirt6  RT-qPCR Assay was purchased from Primer Design 
Sirt7 forward RT-qPCR GCCTCCCTCTTTCTACTCCTTATC 
Sirt7 reverse RT-qPCR TGCTCAGACTGGAGGCTTAGTTA 
Sirt7 probe RT-qPCR TACAAGTGTTCACTTTATAGAAGCCT 
Hmgcr  RT-qPCR Assay was purchased from Primer Design 
Hmgcs1  RT-qPCR Assay was purchased from Primer Design 
Fdft1  RT-qPCR Assay was purchased from Primer Design 
Fdps  RT-qPCR Assay was purchased from Primer Design 
Sqle  RT-qPCR Assay was purchased from Primer Design 
Idi1  RT-qPCR Assay was purchased from Primer Design 
Dhcr7  RT-qPCR Assay was purchased from Primer Design 
Cyp51  RT-qPCR Assay was purchased from Primer Design 
Ampk-α1 RT-qPCR Assay was purchased from ABI 
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Atp5b-Ubc-Gapdh Brain Stem 
 
 
Table 5. Housekeeping genes used for specific brain regions. Primer and probe mixes 
for Atp5b, Canx, Rpl13a, Ubc, Ywhaz were purchased from Primer Design. All RT-qPCR 




Name Application 5’-3’ sequence 
Dbc1 forward Genotyping GTACCTGGAGGGTTTATGTTACCT 
Dbc1 reverse WT Genotyping ACAAGGTCTTAAGTAGCTTGGGCTGGC 
Dbc1 reverse NEO Genotyping CAACCCGTCGGATTCTCCGTG 
HTT exon 1 reverse Genotyping CCTTCATCAGCTTTTCCAGGGT 
HTT exon 1 forward WT Genotyping TTTTCTATCGCTGGTGCCAGG 
HTT exon 1 forward Tg Genotyping CTAGGGCTGTCAATCATGCTGG 
  
Table 6. Primers used for mouse genotyping. 
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2.1.6 Solutions, buffers and gels 
All solutions, buffers and gels were prepared with deionised distilled water (d2H2O). 
 
Inhibitors were added to buffers at the following concentrations: 
1 mM PMFS 
5 μM TSA 
10 mM nicotinamide 
Complete protease inhibitor cocktail (1 tablet in 50ml) 
 
Agarose gel for resolution of PCR products (Prepared in 1xTAE) 
1.5 % (w/v) Ultra pure agarose 
0.1 μg/ml Ethidium bromide 
 
Coomassie staining solution 
0.25% (w/v) Brilliant blue R-250 
50% (v/v) methanol 
10% (v/v) acetic acid 
 
Laemmli loading buffer (2x) 
125 mM Tris–HCl pH 6.8 
20% glycerol 
4% SDS 
0.01% (w/v) bromophenol blue 
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Lysis Buffer for DNA extraction 
50 mM Tris-HCl pH 8.0 
100 mM EDTA 
0.5% (w/v) SDS 
0.5 mg/ml proteinase K 
 
NETN buffer 
20 mM Tris-HCl  pH 8 
100 mM NaCl 




Phosphate buffer saline (PBS) 
137 mM NaCl 
2.7 mM KCl 
100 mM Na2HPO4 
2 mM KH2PO4 
Adjusted pH to 7.4 with HCl 
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Phosphate buffer saline (PBS) -Triton 
137 mM NaCl 
2.7 mM KCl 
100 mM Na2HPO4 
2 mM KH2PO4 
0.1 % (v/v) Triton X100 
Adjusted pH to 7.4 with HCl 
 
Phosphate buffer saline (PBS) -Tween 20 
137 mM NaCl 
2.7 mM KCl 
100 mM Na2HPO4 
2 mM KH2PO4 
0.1 % (v/v) Tween 20 
Adjusted pH to 7.4 with HCl 
 
Resolving Gel 
20-60 % (v/v) (for 6-18% acrylamide gels) Protogel 
25 % (v/v) Protogel resolving buffer 
1 % (w/v) APS 
0.1 % (v/v) TEMED 
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13 % (v/v) Protogel 
25 % (v/v) Protogel stacking buffer 
0.1 % (w/v) APS 
0.2 % (v/v) TEMED 
 
TKM buffer 
50 mM Tris-HCl pH 7.4 
25 mM KCl 
5 mM MgCl2 
0.25 M Sucrose 
Complete Inhibitors 
 
Tris–acetate-EDTA (TAE) buffer (1X) 
40mM Tris Base pH 8.0 
20mM Acetic Acid  
1mM EDTA 
 
Western blot transfer buffer  
25 mM Tris-HCl pH 8.3 
192 mM glycine 
20 % (v/v) methanol 
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2.1.7 Computer programs and internet pages 
AM Logger (Linton Instrument) 
BLAST (NCBI) 
Excel (Microsoft) 
GraphPad (California Corporation) 
ImageJ (National Institute of Health) 
Omega (BMG Labtech) 
Pubmed (NCBI) 
Quantity one (Bio-Rad) 
SPSS statistics software (IBM) 
Vector NTI (Invitrogen) 
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2.1.8 Ethics statement 
All experimental procedures performed on mice were approved by the King's College 
London Ethical Review Process Committee and carried out under a Home Office 
License. 
2.1.9 Mouse Strains 
Hemizygous R6/2 mice (Mangiarini  et al., 1996) were bred by backcrossing R6/2 males 
to (CBA × C57BL/6) F1 females (B6CBAF1/OlaHsd; Harlan Olac). 
HdhQ150/Q150 homozygous mice (Woodman et al. 2007) on a (CBA×C57BL/6)F1 
background were generated by intercrossing HdhQ150/Q7 heterozygous CBA/Ca and 
C57BL/6J congenic lines (inbred lines from Harlan Olac).  Dbc1 heterozygous mice were 
obtained from the Mayo Foundation, Mayo Clinic College of Medicine, Rochester, 
Minnesota, USA (Escande et al., 2010).  SirT1 floxed homozygous (SirT1 Fl/Fl) mice 
were obtained from the JAX Laboratory (Mouse Strain: B6;129-SirT1tm1Ygu/J) and 
were bred with β-actin/cre heterozygous mice to generate complete Sirt1KO mice.  
Sirt1 heterozygous transgenic mice (CBA×C57BL/6J) were obtained from Washington 
University MI. 
2.1.10 Mouse husbandry 
At 4 weeks of age, mice were weaned into cages of 5 - 6 animals (Dbc1KO x R6/2 
phenotypic assessment study only). Each cage contained at least one representative of 
each genotype. Animals were housed under 12 h light / 12 h dark cycle, with unlimited 
access to water and food (Special Diet Service, Witham, UK). Cages were 
environmentally enriched with a cardboard tube (Hockly et al., 2003). R6/2 mice and 
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all mice in phenotypic assessment trials were always given mash food consisting of 
powered chow mixed with water from 14 weeks of age until sacrificed. 
2.1.11 Mouse genotyping and repeat sizing 
All mice were genotyped by PCR of tail tips or ear punches. Tail tips or ear punches 
were collected at 10 - 14 days of age. The tissue was digested O/N in 300 μl of lysis 
buffer at 55:C. DNA was precipitated using 200 μl of isopropanol. The DNA was 
pelleted by centrifugation at 13,000 x g for 15 min. The supernatant was discarded and 
pellets were washed with 70% ethanol, spun for 10 min at 13,000 x g and the 
supernatant removed. Pellets were air dried until all ethanol had evaporated and then 
re-suspended in 100 µl of 5 mM Tris HCl, pH 7.5.  
 Dbc1KO mice were genotyped with 1 µl of each primer (3 primers) (Table 6) 
diluted 1:8 (10 µM). 25 µl multiplex reaction also containing 1 µl 50 ng/µl DNA, 2 µl 10 
mM dNTP, 5 µl 5X Green GoTaq Reaction Buffer and 0.125 µl GoTaq polymerase. 
Cycling condition were as follows: 94:C for 5 min, (94:C for 30 s, 62:C for 25 s and 72:C 
for 45 s) x35, followed by 6 min at 72:C. 
 R6/2 mice were genotyped with 1 µl of HTT exon1 forward Tg and WT primers 
diluted 1:10 (10 µM) and 1:5 (20 µM) respectively (Table 6). 25 µl multiplex reaction 
also containing 1 µl 50 ng/µl DNA, 2 µl 10 mM dNTP, 5 µl 5X Green GoTaq Reaction 
Buffer and 0.125 µl GoTaq polymerase. Cycling condition were as follows: 94:C for 5 
min, (94:C for 30 s, 62:C for 25 s and 72:C for 45 s) x35, followed by 6 min at 72:C. 
 Amplification of the CAG repeat from R6/2 tail DNA was performed with a FAM 
labelled forward primer and an unlabelled reverse primer in 10 µl reaction containing 
100 ng DNA, 0.2 mM dNTPs, 10% DMSO, 1X AM Buffer and 0.5 U AmpliTaq DNA 
polymerase, using cycling condition of 90 s at 94:C, 94:C for 30 s, 65:C for 30 s and 
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72:C for 90 s) x24, followed by 10 min at 72:C. Sequencing reactions (FAM-tagged PCR 
product (1 µl), internal MegaBACE ET90 size standard (0.04 µl) and HiDi-formamide (9 
µl)) were denatured at 94:C for 5 min before analysis of products using an ABI3730 
sequencer. Data analysis was performed using GeneMapper v5.2 - 3730xl.  
2.1.12 Mouse behavioural analysis 
All tests were performed blind to the genotype. Body weight and brain weight were 
determined, immediately after cervical dislocation, using a digital balance.  
 Forelimb grip strength was assessed at 4 weeks of age and then bi-weekly from 7 
weeks of age using a grip strength meter. To measure grip strength, mice were swung 
gently by the tail so the central bar was securely gripped by the forelimbs. Mice were 
pulled backwards until the grip on the metal frame was released. The force exerted 
was recorded by the meter. Five measurements were performed and the best three 
scores were used for statistical analysis.  
 Motor coordination was assessed using an Ugo Basile 7650 rotarod, modified to 
accelerate from 4 to 44 rpm over 300 s. Bicycle inner tubing (Evans Cycle, London, UK) 
was used to cover the ridges on the plastic drum to provide a smooth non-slip surface. 
Mice were placed on the rotarod drum for 20 s for acclimatisation before the rotarod 
was allowed to accelerate. Mice were measured three times a day for 4 days at 4 
weeks of age. At 6-, 8-, 10-, 12- and 14 weeks of age, mice were tested three times a 
day for three days. Data for the first day were not used for statistical analysis. 
 Spontaneous exploratory motor activity was measured bi-weekly from 5 - 13 
weeks of age by placing mice individually in the AM1053 activity cages for 30 min 
during the light phase. Each cage measured 367 x 207 x 140 cm, had a thin layer of 
wood chippings, four food pellets and a water bottle distributed so as not to interfere 
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with the array of infrared beams that measured the mouse activity and mobility. Mice 
were tested at the same time of day, with male mice always tested before female mice 
and cages cleaned thoroughly in between the two sexes. Data collection was started 
immediately after the mouse was placed in the activity cage, by the AM logger 
software recording the number or beam breaks occurring in 1 min intervals. Data was 
then exported to Microsoft Excel and analysed for activity (total number of beam 
brakes in the lower level), mobility (at least two consecutive beam breaks in the lower 
level), rearing (beam breaks in the upper level) and centre rearing (beam breaks in 
upper level away from the cage walls). 
2.1.13 Tissue preparation 
Dissected half brains, brain regions or peripheral tissues were snap frozen in liquid 
nitrogen and stored at –80:C.  
2.1.14 Protein extraction for SDS-PAGE, Western Blotting and Immunoprecipitation 
Frozen mouse brain tissue was homogenized in 1 volume of ice cold NETN buffer using 
a polytron homogenizing probe. Samples were sonicated on ice with vibracell sonicator 
(10 x 1 s 20 kHz pulses) and spun at 13,000 x g for 10 min at 4:C. The supernatant was 
retained and protein concentrations were determined for each sample by BCA assay. 
2.1.15 SDS-PAGE and Western blotting 
Protein lysates were diluted with 2X Leammli Buffer and denatured for 10 min at 95:C. 
Samples, containing an equal amount of protein were loaded for SDS-PAGE analysis. 
Proteins were separated by running gels at 130 V in 1X SDS-PAGE running buffer and 
the migration of proteins was determined using the Spectra pre-stained protein 
marker. Proteins were transferred onto a nitrocellulose membrane at 120 V for 75 min 
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by submerged transfer apparatus in transfer buffer.  Membranes were then blocked in 
5% non-fat dried milk in PBS – 0.2% Tween 20 (PBS-T) or 4% BSA for 2 h at RT. Primary 
antibodies were added overnight at 4:C in 5% non-fat dried milk in PBS-T (DBC1, SIRT1, 
EM48, Fl-HTT, AMPKα1) or 4% BSA in PBS-T (MpM2). For loading controls of 
cytoplasmic and nuclear fractionations, membranes were incubated with either β-
actin, ATP5B, α-tubulin and histone Pan-H3 for 20 min at RT in 5% non-fat dried milk in 
PBS – 0.2% Tween 20 (PBS-T). Blots were washed three times for 10 min in 0.2% PBS-T 
and incubated with the appropriate secondary antibody. The signal was developed 
using ECL hyper-film and a Xenograph developer. Densitometry of the western blot 
was performed using a GS-800 densitometer. Developed films were scanned and each 
band was quantified using QuantityONE. The average pixel density (OD) was measured 
and the values obtained from the bands of interest were normalised to the OD of α-
tubulin, ATP5B or β-actin.  
All antibodies used are summarized in Table 3. 
2.1.16 Immuno-precipitation 
Protein lysates were prepared for IP as described above. Immunoprecipitation 
reactions were performed in 1 ml of NETN buffer containing from 400 to 1000 µg 
protein and 1 μg of antibody. Normal rabbit IgG (#2729; Cell Signalling) was used as a 
negative control. 15 μl of protein G-magnetic beads were added for the last 45 min. 
Reactions were left on a rotating wheel at 4:C for 90 min (AMPKα1) or 4 h (SIRT1 and 
DBC1), following which, protein G-magnetic beads were pelleted by brief 
centrifugation at 13,000 x g for 30 s, put on a magnetic rack, washed 4X with 1 ml of 
NETN buffer and re-suspended in 15 μl of 2X Leammli buffer. Immuno-precipitated 
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complexes were eluted from the beads by denaturation at 100:C for 10 min and 
immediately loaded for SDS-PAGE analysis. 
2.1.17 Nuclear/Cytoplasmic fractionation 
All steps were performed on ice. Brain tissue was cut into small pieces and 
homogenized 10X with a Dounce homogenizer in TKM buffer (0.25 M sucrose; 50 mM 
Tris-HCl, pH 7.4; 25 mM KCl; 5 mM MgCl2 and 1 mM PMSF). The homogenate was 
filtered through cheesecloth and centrifuged twice at 800 x g for 10 min. The 
supernatant, containing the cytoplasmic fraction, was cleared with a centrifugation at 
13,000 x g for 10 min. The resuspended pellet was added to the top of tubes that 
contained an equal volume of a cushion composed (from top to bottom) of 0.5 ml 1.0 
M sucrose solution, 0.5 ml 1.5 M sucrose solution, and 1.5 ml 2.1 M sucrose solution, 
all in TKM buffer. Tubes were centrifuged at 28000 x g for 60 min, and the resulting 
pellet was resuspended in homogenizing medium and sedimented at 800 x g for 10 
min. The final pellet containing the purified nuclei was resuspended in 4% PFA to 
perform an immunohistochemical analysis or in NETN buffer and protein 
concentration was determined for each sample by BCA assay. 
2.1.18 Immunohistochemistry 
Isolated brain nuclei were extracted as described above. Samples were fixed on the 
slide for 30 min with 4% paraformaldehyde prepared in PBS, permeabilized with 0.1% 
Triton X-100 in PBS for 15 min, washed 3X with PBS, and incubated for 1 h at RT in 
blocking buffer (PBS with 0.1% Triton and 1% BSA). Nuclei were incubated with the 
primary antibody in blocking buffer (DBC1, SIRT1, P53 and Ac-P53) overnight at 4:C, 
washed 3X with PBS at RT and then incubated with the secondary antibody and DAPI in 
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PBS-0.1% Triton for 1 h at RT. Samples were mounted using VECTASHIELD mounting 
medium. Nuclei were visualized using a Leica confocal microscope. 
2.1.19 RNA extraction 
RNA extraction was performed using QIAZOL, an RNeasy mini-kit and Rnase-free 
DNaseI supplied by Qiagen, according to manufacturer's instructions. All steps were 
performed at RT. Frozen mouse tissues were homogenized in 0.5 ml of QIAZOL using a 
polytron homogenization probe and snap-frozen on dry ice. After thawing, the 
homogenates were left for 5 min at RT. Subsequently, 200 μl of chloroform was added 
and the homogenates were shaken vigorously for 10 s and spun at 11400 x g for 15 
min at 4:C and the resulting upper aqueous phase was transferred to a new 
polypropylene tube containing 300 μl of 70% ethanol. After mixing, samples were 
transferred to an RNeasy Mini spin column in a 2 ml collection tube. Binding of the 
RNA and all subsequent washing steps were achieved by centrifugation for 15 s at 
13,000 x g. Columns were washed with 350 μl buffer RW1 (provided with the kit) and 
80 μl of Qiagen RNase-free DNaseI (10 μl DNaseI stock in 70 μl RDD buffer) was added 
to the column and incubated at RT for 30 min. Columns were washed again with 350 μl 
buffer RW1 and then twice with 500 μl buffer RPE (provided with kit). Columns were 
spun again at 13,000 x g to remove any residual buffer. Columns were placed in 1.5 ml 
collection tubes and 40 μl of RNase-free water was added directly to column 
membranes and incubated for 1 min before centrifugation. RNA concentrations were 
assessed by measuring the absorbance at 230 nm and 260 nm by a nanodrop 
spectophotometer (Thermo Scientific) for each sample. 
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2.1.20 cDNA synthesis 
Reverse transcription reactions were performed by adding 1 μg of total sample RNA to 
9 μl of DEPC water, 2 μl of DTT (0.1 M) and 1 μl of random hexamers (100 ng/μl). 
Samples were then incubated at 94:C for 2 min. 8 μl of mastermix (0.75 μl DepC H2O, 4 
μl MMLV-RT 1st strand buffer (5X), 2 μl dNTPs (10 mM) and 0.25 μl of RNAsin was 
added to each sample. Reverse transcription reactions were performed in a Dyad 
thermocycler using conditions of 23:C for 10 min, 37:C for 40 min and 95:C for 5 min. 
The resulting cDNA was cooled to 4:C and diluted 1:10 with ultra-pure water.  
2.1.21 Real time quantitative PCR (qPCR) 
Taqman RT-qPCR reactions were performed in triplicate for each sample using white 
96 well PCR plates and the CFX96 Real-Time System (Bio-Rad). For assays purchased 
from Primer Design, 3 μl of cDNA was incubated with 0.6 μl primer/probe mix, 6 μl 
precision Master Mix (2X) and 2.4 μl water. For other assays, 3 μl of cDNA was 
combined with 0.45 μl of each primer (100 μM), 0.3 μl of probe (100 μM), 7.5 μl of 
precision Master Mix (2X) and 3.3 μl of water. The reactions for houskeeping genes 
were incubated for 10 min at 95:C, followed by 40 cycles of 95:C for 15 s, 50:C for 30 s 
and data were collected. The reaction for genes of interest incubated for 10 min at 
95:C, followed by 40 cycles of 95:C for 15 s, 60:C for 30 s and data were collected. 
Gene expression was then calculated relative to levels of houskeeping genes using the 
ΔCt method.  
All Taqman RT-qPCR primers used are summarized in Table 4 
Chapter 2                                                                     Materials and Methods 




2.1.22 Fluor de Lys assay 
SIRT1 activity was determined with a SIRT1 Fluorometric Kit (Biomol International) 
according to the manufacturer’s instructions. Protein extraction was performed as 
described above. Homogenates were then incubated for 10 min at 37:C to allow 
degradation of any contaminant NAD+. Next, 10 mM DTT was added to the medium, 
and homogenates were incubated again for 10 min at 37:C. The homogenates (20–30 
μg protein/well) were then incubated in SIRT1 assay buffer in the presence of either 
100 μM Fluor de Lys–SIRT1 substrate (Enzo Life Sciences) and 5 μM TSA to determine 
the SIRT1-independent activity, or with 100 μM Fluor de Lys–SIRT1 substrate, 5 μM 
TSA, and 200 μM NAD+ to determine the SIRT1-dependent activity. After 60 min of 
incubation at 37:C, the reaction was terminated by adding a solution containing Fluor 
de Lys Developer (Enzo Life Sciences) and 2 mM nicotinamide. Plates were incubated 
at 37:C for 0-, 20-, 40- and 60 minutes. Values were determined by reading 
fluorescence on a fluorometric plate reader (Spectramax Gemini XPS; Molecular 
Devices) with an excitation wavelength of 360 nm and an emission wavelength of 460 
nm.  
2.1.23 Statistical Analysis 
Statistical analysis was performed with SPSS (one-way ANOVA multiple comparisons 
and repeated measures ANOVA General Linear Model) or Microsoft Excel (Student's t-
test) software. For mouse phenotypic assessment, weight, rotarod and grip strength 
were analysed with repeated measures ANOVA and at each time point with one-way 
ANOVA multiple comparisons. Brain weight was analysed by one-way ANOVA multiple 
comparisons. Activity was analysed with repeated measures ANOVA at each time point 
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separately. For western blotting, IP and qPCR, group means were compared by 
Student's t -test or one-way ANOVA multiple comparisons. 
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Chapter 3                                                                                                         
RESULTS: SIRT1 ACTIVITY IS IMPAIRED IN HD MOUSE MODELS 
3.1 Measurement of SIRT1 activity in the mouse brain 
There is considerable evidence to support a beneficial effect of SIRT1 overexpression in 
HD mouse models, although the impact of this pathology on SIRT1 functions has not 
been fully elucidated. As such, we decided to analyse SIRT1 activity and the 
mechanisms involved in its regulation in two different HD mouse models, R6/2 and 
HdhQ150 homozygous mice.  
To measure SIRT1 activity in the HD brains we needed an assay able to detect 
specifically SIRT1 activity. Interestingly, studies have demonstrated that SIRT1 binds to 
and regulates the activity of several transcription factors among which is P53 (Langley 
et al., 2002). SIRT1 can interact with and deacetylate P53 on Lys382 inhibiting its 
function (Solomon et al., 2006). Indeed, we tested two different assays able to 
measure the ability of SIRT1 to deacetylate P53: 
1. Fluor de Lys assay (BML-AK555) 
2. Immunohistochemistry assay on isolated nuclei 
3.2 Measurement of SIRT1 activity with Fluor de Lys assay  
To validate a method for measuring SIRT1 activity in mouse tissues we used the 
commercial kit (BML-AK555). This assay uses a small lysine-acetylated peptide, 
corresponding to K382 of human P53, as a substrate. The lysine residue is deacetylated 
by SIRT1, and this process is dependent on the addition of exogenous 
NAD+. Deacetylation of the substrate sensitises the substrate so that, in the second 
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step, treatment with the Fluor de Lys-Developer II produces a fluorophore (Fig. 15). 





Figure 15. Reaction scheme of the SIRT1 Fluorescent Activity Assay. NAD+-dependent 
deacetylation of the substrate by recombinant human SIRT1 sensitizes it to Developer 
II, which then generates a fluorophore (symbol). The fluorophore is excited with 360 
nm light and the emitted light (460 nm) is detected on a fluorometric plate reader. 
NAD+ is consumed in the reaction to produce nicotinamide (NAM) and O-acetyl-ADP-
ribose. 
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In order to investigate the specificity of the Fluor de Lys assay for SIRT1 activity, we 
performed a test including WT samples, SIRT1-recombinant human protein and Sirt1-/- 
knock-out (Sirt1KO) samples at three different substrate concentrations (50 µM, 100 
µM and 200 µM): 
 WT sample: we added the cortex lysate from WT mice, the substrate and NAD+  
 SIRT1-recombinant human protein: we added SIRT1 recombinant human 
protein, the substrate and NAD+ 
 Sirt1KO sample: we added the cortex lysate from Sirt1KO mice, the substrate 
and NAD+ 
Unfortunately, no differences could be detected with the Fluor de Lys assay between 
WT and Sirt1KO tissues (Fig. 16). This result suggests that the Fluor de Lys assay (BML- 
AK555) is not specific for SIRT1 activity and that it is not an appropriate tool to 
measure SIRT1 activity in animal tissue lysates. 
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Figure 16. Measurement of SIRT1 activity with Fluor de Lys assay. Fluorescence signal 
obtained after 0, 20, 40 and 60 minutes of incubation at 37 :C. 25 µg of protein from 
cortex lysates of WT or Sirt1KO mice and 2U/well of SIRT1-recombinant protein were 
incubated with 50, 100 or 200 µM of substrate and with 200 µM of NAD+. 
N=2/genotype. 
  
Chapter 3                                                                   SIRT1 activity in HD mice 




3.3 Measurement of SIRT1 activity with immunohistochemistry on isolated 
nuclei. 
To monitor SIRT1 activity on P53, we isolated cell nuclei from mouse brains to perform 
an immunostaining assay. To confirm the specificity of this assay we immunostained 
nuclei extracted from half brains of Sirt1KO and Sirt1 transgenic (Sirt1Tg) mice at 4 
weeks of age. Nuclei were immunostained for SIRT1, P53 and acetylated-P53 (AcP53), 
and counterstained with DAPI. To measure specifically SIRT1 activity we used an 
acetylated-P53 antibody able to recognize the acetylation of a Lys- residue that can be 
deacetylated only by SIRT1. We did not detect any variation in the intensity level of 
P53 staining between Sirt1KO and Sirt1Tg mice samples and the corresponding WT 
(Fig. 17 A and B). Interestingly, we also observed increased levels of AcP53 in the brain 
of Sirt1KO mice and a decrease in the acetylation of endogenous P53 in the Sirt1Tg 
samples, consistent with a decrease in SIRT1 activity in the knock-out line and an 
increase in SIRT1 activity in the transgenic line respectively (Fig. 17 A and B). The 
genotypes of the mice used for the experiment were confirmed by western blot (Fig. 
18 C). This result suggests that the immunohistochemistry assay is specific for SIRT1 
activity and that it is an appropriate tool to measure SIRT1 activity in animal tissues.  
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Figure 17. SIRT1 activity is reduced in SIRT1 knock-out and increased in SIRT1 
transgenic mice. (A) Representative immunofluorescence image of isolated nuclei 
extracted from half brains from Sirt1KO and Sirt1Tg mice brains at 4 weeks of age 
immunostained for P53 and AcP53 and counterstained with DAPI. To measure 
specifically SIRT1 activity we used an acetylated-P53 antibody able to recognize the 
acetylation of a Lys- residue that can be deacetylated only by SIRT1. (B) Relative 
intensity level of P53 and AcP53 from the immunostained nuclei shown in A. The 
quantification indicates that the level of acetylated p53 is higher in the Sirt1KO mice, 
consistent with a decrease in SIRT1 activity and lower in Sirt1Tg mice, consistent with a 
increase in SIRT1 activity.  Data are the mean ± SEM. *** p<0.001. Scale bar, 10 µm; 
n=4 / genotype. 
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3.4 Sirt1KO mice express the inactivated form of SIRT1 
Previously we showed that Sirt1KO mice are characterized by a decrease in SIRT1 
function. Despite this, they did not show any reduction in the intensity level of SIRT1 as 
compared to WT littermates (Fig. 18 A and B). The western blot analysis shows clearly 
that the full-length form of SIRT1 is not produced in the Sirt1KO mice and the SIRT1 
doublet (first and second band from the top) is shifted down as compared to WT and 
Sirt1 transgenic mice (Fig. 18 C). The unchanged intensity level of SIRT1 in the 
immunohistochemistry and the shift of SIRT1 doublet in Sirt1KO mice, shown by 
western blot, indicate that the mechanism used to induce the ablation of SIRT1 in 
these mice is not able to knock out the protein but it is efficient to inactivate SIRT1.  
The region that encode for the catalytic domain of SIRT1 is located in the exon 4. To 
generate the Sirt1KO mice the exon 4 has been floxed (Fig. 18 D). Since the exon 4 
comprises 153 bp when it is removed the reading of the protein is still in frame 
promoting the translation of the inactivated form of SIRT1. Without the exon 4 the 
translated protein is less heavy as compared to the full-length and this can explain the 
shift down of the SIRT1 doublet. The antibody used to detect SIRT1 recognizes a C-
terminal amino acid epitope (722-737 aa) of mouse SIRT1, this further confirms the 
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Figure 18. SIRT1 levels in SIRT1 knock-out and SIRT1 transgenic mice. (A) 
Representative immunofluorescence image of isolated nuclei extracted from half 
brains from Sirt1KO and Sirt1Tg mice brains at 4 weeks of age immunostained for 
SIRT1 and counterstained with DAPI. (B) Relative intensity level of SIRT1 from the 
immunostained nuclei shown in A. (C) Representative western blot for SIRT1 in half 
brains from Sirt1KO and Sirt1Tg mice at 4 weeks of age. (D) Mouse Sirt1 wild-type 
allele (Sirt1+), conditional targeted allele (Sirt1co), and knockout allele (Sirt1ko). Data are 
the mean ± SEM. *** p<0.001. Scale bar, 10 µm; KO: Sirt1KO; Tg: Sirt1Tg. n=4 / 
genotype.  
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3.5 Sirt1tg mice overexpress SIRT1 
The Sirt1 transgenic mouse line was generated by the overexpression of the 
hemagglutinin-tagged (HA tagged) Sirt1 transgene driven by the mouse prion protein 
promoter (PrP). The Sirt1 transgene (HA tagged) was constructed by inserting a 2.3-kb 
fragment of mouse Sirt1 cDNA into the vector carrying the mouse PrP promoter. The 
PrP-Sirt1-HA transgene was linearized, purified and microinjected into C57BL/6J × CBA 
hybrid blastocysts in the Washington University Mouse Genetic Core Facility (Satoh et 
al., 2010). The Sirt1Tg tissues show an increase of the intensity level of SIRT1 staining 
followed by an increase of SIRT1 activity , as compared to WT littermates (Fig. 17 A and 
B, Fig. 18 A and B). The genotype is also confirmed by western blot (Fig. 18 C). 
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3.6 SIRT1 function is progressively compromised in the brains of HD mice 
To understand the impact of HD pathology on SIRT1 activity, we isolated cell nuclei 
from half brains of R6/2 mice at 4, 9 and 14 weeks of age, HdhQ150 homozygous mice 
at 2 and 22 months of age and aged-matched control WT mice. Nuclei were 
immunostained for SIRT1, P53 and acetylated-P53 (AcP53), and counterstained with 
DAPI. Notably, we did not detect any variation in the intensity level of SIRT1 and P53 
staining between HD samples and the corresponding WT at each age of analysis (Fig. 
19 A and B). Interestingly, we found that the levels of acetylation of endogenous P53 
was equivalent in HD as compared to WT brains at an early stage of the disease (i.e. 4 
week R6/2 and 2 month HdhQ150 homozygous), whereas the level of AcP53 was 
significantly higher (≥ 1.5 fold) in the HD samples as the disease progressed, suggesting 
that SIRT1 activity became impaired in the brains of HD mice (Fig. 19 A and B). 
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Figure 19 A. SIRT1 activity became reduced with disease progression in HD mouse 
models. Representative immunofluorescence image of isolated nuclei extracted from 
half brains from R6/2 mice at 4, 9 and 14 weeks of age and HdhQ150 homozygous at 2 
and 22 months immunostained for SIRT1, P53 and AcP53 and counterstained with 
DAPI. To measure specifically SIRT1 activity we used an acetylated-P53 antibody able 
to recognize the acetylation of a Lys- residue that can be deacetylated only by SIRT1. 
Hdh, HdhQ150 homozygotes. n=4 / genotype. 
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Figure 19 B. SIRT1 activity became reduced with disease progression in HD mouse 
models. Relative intensity level of SIRT1, P53 and AcP53 from the immunostained 
nuclei shown in A. The quantification indicates that the level of acetylated P53 is 
higher in the HD models, consistent with a decrease in SIRT1 activity. Data are the 
mean ± SEM. ***p<0.001. Scale bar, 10 µm. Hdh, HdhQ150 homozygotes. n=4 / 
genotype. 
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3.7 SIRT1 does not co-localize with mutant HTT inclusions and is aberrantly 
phosphorylated in HD mice  
Previous studies showed that SIRT1 interacts with HTT in vitro (Jeong et al., 2011). To 
rule out the sequestration of SIRT1 into mHTT inclusions as the cause of altered SIRT1 
activity, we performed a double staining for SIRT1 and HTT (EM48) on nuclei isolated 
from half brains of 14 week R6/2, 22 month HdhQ150 homozygous and age-matched 
WT mice. Interestingly, we did not detect a co-localization of SIRT1 with mHTT 
inclusions (Fig. 20 A). To further support this finding, we did not observe any reduction 
in SIRT1 protein in HD brains by western blot as compared to WT mice (Fig. 20 B). 
The role of post-translational modifications (PTMs) in the regulation of SIRT1 activity 
has been the subject of several studies and phosphorylation has been described as a 
major control mechanism (Sasaki et al., 2008) (Fig. 10). Therefore, in the attempt to 
understand how mHTT can affect SIRT1 activity, we decided to monitor the 
phosphorylation status of SIRT1 in HD mice. We performed SIRT1 immunoprecipitation 
from half brains of R6/2 mice at 9 weeks of age and HdhQ150 homozygous mice at 22 
months of age and detected the phosphorylation level of SIRT1 by western blot using 
MpM2 antibody (Westendorf et al., 1994). MpM2 antibody can be used to detect 
phosphorylation on Serine and Threonine residues followed by Proline (S/T-P sites) 
present on any protein and it is not specific for any particular phosphorylation sites 
(full sequence of SIRT1 protein and residues Ser-Pro and Thr-Pro can be found in the 
Appendix 1). Interestingly, both R6/2 and HdhQ150 homozygous showed a higher level 
of phosphorylated SIRT1 as compared to the corresponding WT mice (Fig. 20 C). As 
previously shown in vitro (Jeong et al., 2011), we were also able to co-
immunoprecipitate endogenous full-length wild-type HTT from R6/2 lysates and both 
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mutant and wild-type HTT from HdhQ150 homozygous and WT lysates respectively 
(Fig. 20 C). 
These results suggest that the impairment of SIRT1 function in the brain of HD mice 
may not be related to a sequestration into mHTT inclusions and that the link might be 
found in an altered phosphorylation profile. 
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Figure 20. SIRT1 does not co-localize with HTT inclusions and is aberrantly 
phosphorylated in HD mice. (A) Representative immunofluorescence image of isolated 
nuclei extracted from half brains from R6/2 mice at 14 weeks of age and HdhQ150 
homozygotes at 22 months immunostained for both SIRT1 and mHTT (EM48), and 
counterstained with DAPI. (B) Representative western blot showing SIRT1 levels in half 
brains from R6/2 mice at 14 weeks of age and HdhQ150 homozygotes as compared  to 
their WT littermates. Note the shift of Fl-HTT in HdhQ150 homozygous mice as 
compare to WT littermates. (C) Western blots of SIRT1, phosphorylated SIRT1 (MpM2) 
and HTT after SIRT1 immunoprecipitation from half brain lysates of R6/2 and HdhQ150 
homozygotes as compared to their WT littermates. MpM2 antibody (used to detect 
the phosphorylation profile of SIRT1) is able to detect the phosphorylation on Serine 
and Threonine residues followed by Proline (S/T-P sites) present on any protein and it 
is not specific for any particular phosphorylation sites. IP, immunoprecipitation; WB, 
western blotting; Hdh, HdhQ150 homozygotes. Scale bar, 10 µm. Data representative 
of at least three independent experiments. 
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3.8 Progressive decrease in SIRT1 phosphorylation in the striatum and 
increase in the cerebellum of HD mice 
HD neuropathology hallmarks are more pronounced in the striatum and cortex than 
other brain regions (Bates, Tabrizi and Jones, 2014). Therefore the analysis of half 
brains might mask or dilute any regional pathological changes. As such, we decided to 
extend the analysis of SIRT1 phosphorylation to the striatum, cortex and cerebellum, 
and to include different ages to highlight any link to the progression of the disease. 
Interestingly, we did not detect any difference in the phosphorylation status of SIRT1 
at presymptomatic stages of the disease (i.e. 4-week-old R6/2 and 2-month-old 
HdhQ150 homozygous mice) between HD mice and their WT littermates in any brain 
regions (Fig. 21 A, B, C, D and E). In keeping with our functional data obtained from half 
brain, which showed an impairment of SIRT1 activity by 9 weeks of age in R6/2 and in 
22-month-old HdhQ150 homozygous mice, we observed an altered phosphorylation 
level of SIRT1 both in the striatum and cerebellum of R6/2 mice by 9 weeks of age (Fig. 
21 A and C) and in 22-month HdhQ150 homozygous mice (Fig. 21 B and D). 
Surprisingly, the level of phosphorylation of SIRT1 remained unchanged in the cortex 
of R6/2 mice at these later stages (Fig. 21 E). Notably, we detected a reduction in the 
phosphorylation level of SIRT1 in the striatum of R6/2 and HdhQ150 homozygous mice, 
whereas phosphorylation was higher in the cerebellum of both HD models as 
compared to WT littermates (Fig. 21 A, B, C and D). Taken together, these results 
demonstrate that the presence of mHTT affects the phosphorylation status of SIRT1 as 
the disease progresses and that the changes go in the opposite direction for the 
striatum and cerebellum. 
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Figure 21. SIRT1 phosphorylation is altered in HD mouse models.  (A, B) Western blots 
of SIRT1 and phosphorylated SIRT1 (MpM2) after SIRT1 immunoprecipitation from the 
striatum of R6/2 mice at 4, 9 and 14 weeks of age and HdhQ150 homozygotes at 2 and 
22 months as compared to their WT littermates. (C, D) Western blots of SIRT1 and 
phosphorylated SIRT1 after SIRT1 immunoprecipitation from the cerebellum of R6/2 
mice at 4, 9 and 14 weeks of age and HdhQ150 homozygotes at 2 and 22 months as 
compared to their WT littermates. (E) Western blots of SIRT1 and phosphorylated 
SIRT1 after SIRT1 immunoprecipitation from cortical lysates of R6/2 mice at 4, 9 and 14 
weeks of age compared to WT littermates.  IP, immunoprecipitation; WB, western 
blotting; Hdh, HdhQ150 homozygotes. Data representative of at least three 
independent experiments. 
Chapter 3                                                                   SIRT1 activity in HD mice 




3.9 Induction of SIRT1 activity is blocked in the striatum 
Phosphorylation plays a central role in controlling protein activity, cellular localization 
and degradation (Johnson LN, 2009). To determine whether the differentially altered 
phosphorylation profile of SIRT1 in striatum and cerebellum corresponded to a 
compromised SIRT1 function in both these brain regions, we immunostained for SIRT1, 
P53 and AcP53 nuclei isolated from striatum and cerebellum of R6/2 and WT mice at 4, 
9 and 14 weeks of age. Consistent with the data obtained from half brain, we did not 
detect any change in the intensity level of SIRT1 and P53 staining either the striatum or 
cerebellum between R6/2 and WT mice, at any of the age studied (Fig. 22 A and C, Fig. 
23 A and C). Interestingly, we observed a significant reduction in the level of AcP53 in 
the striatum of WT mice, corresponding to an increase in SIRT1 activity, from 4 to 14 
weeks of age, which was absent in the striatum of R6/2 mice (Fig. 22 B). In contrast, 
when we analysed SIRT1 activity in the cerebellum we detected no change in the level 
of AcP53 in WT samples at these ages and a significant progressive increase of AcP53 
in the cerebellum of R6/2 mice from 4 to 14 weeks of age (Fig. 23 B), corresponding to 
a progressive impairment in SIRT1 activity. These data highlight for the first time that 
SIRT1 activity is regulated by different mechanisms in the striatum and cerebellum of 
WT mice between 4 and 14 weeks of age. SIRT1 activity is induced in the striatum 
between 4 and 9 weeks of age, whereas it remains constant in the cerebellum. The 
presence of mHTT can block this induction process in the striatum and causes a 
reduction of normal SIRT1 function in the cerebellum, resulting in an impairment of 
SIRT1 activity in both brain regions. 
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Figure 22. The induction of SIRT1 activity is blocked in the striatum Representative 
immunofluorescence image of isolated nuclei extracted from the striatum of WT and 
R6/2 mice at 4, 9 and 14 weeks of age immunostained  for (A) SIRT1, (B) AcP53 and (C) 
P53, and counterstained with DAPI. The relative intensity levels of SIRT1, P53 and 
AcP53 are depicted alongside. The quantification indicates that the level of acetylated 
P53 is lower in WT mice, consistent with an increase in SIRT1 activity with age. Scale 
bar, 10 µm. Data are the mean ± SEM. *** p<0.001: statistically significant difference 
compared to 4 week WT. ### p<0.001: statistically significant difference between R6/2 
and WT. n=4 / genotype. 
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Figure 23. SIRT1 activity is impaired in the cerebellum Representative 
immunofluorescence image of isolated nuclei extracted from the cerebellum of WT 
and R6/2 mice at 4, 9 and 14 weeks of age immunostained  for (A) SIRT1, (B) AcP53 and 
(C) P53, and counterstained with DAPI. The relative intensity levels of SIRT1, P53 and 
AcP53 are depicted alongside. The quantification indicates that the level of acetylated 
P53 is higher in R6/2 mice, consistent with a decrease in SIRT1 activity with age. Scale 
bar, 10 µm. Data are the mean ±SEM. *** p<0.001: statistically significant difference 
compared to 4 week WT. ### p<0.001: statistically significant difference between R6/2 
and WT. n=4 / genotype   
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3.10 Striatum-specific age-dependent phosphorylation controls SIRT1 
induction  
The comparison of SIRT1 activity in the striatum and cerebellum between R6/2 and WT 
mice at different ages revealed the existence of different mechanisms to control SIRT1 
function between these two brain regions in WT mice. In addition, these findings 
provide evidence of a striatum-specific mechanism by which SIRT1 is activated with 
age. This process does not occur in the cerebellum. To monitor the phosphorylation 
level of SIRT1 in normal physiological conditions in different brain regions, we 
immunoprecipitated SIRT1 from the striatal and cerebellar lysates of WT mice at 4, 9 
and 14 weeks of age and immunoprobed with the MpM2 antibody to detect the 
phosphorylation status of SIRT1. Notably, we observed a fluctuation in the level of 
SIRT1 phosphorylation in the striatum (Fig. 24 A), whereas SIRT1 phosphorylation 
remained constant in the cerebellum (Fig. 24 B), between ages.  
 Specifically, the level of SIRT1 phosphorylation in the striatum dramatically 
dropped between 4 and 9 weeks of age, when the functional data revealed an increase 
in SIRT1 activity (Fig. 22 B), and then went up again at 14 weeks of age (fig. 24 A), stage 
at which the functional data still highlighted an higher (~50%) degree of activity of 
SIRT1 as compared to 4 weeks of age (Fig. 22 B). Conversely, SIRT1 activity remains 
constant during these ages in the cerebellum and this reflect a phosphorylation level 
that does not change. It is worth mentioning, again, that MpM2 antibody detects 
phosphorylation on Serine and Threonine residues followed by Proline (S/T-P sites) and 
it is not specific for any particular SIRT1 phosphorylation sites; therefore, the 
phosphorylation signals at 4, 9 and 14 weeks might be the results of phosphorylation 
on different residues of SIRT1. Taken together these data provide a link between the 
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phosphorylation status of SIRT1 and its activity, suggesting that in the striatum a 
change in SIRT1 phosphorylation level between ages might be related to an induction 






Figure 24. The phosphorylation status of SIRT1 changes in the striatum but not in the 
cerebellum with age. Western blots of SIRT1 and phosphorylated SIRT1 after SIRT1 
immunoprecipitation from (A) the striatum of WT mice at 4, 9 and 14 weeks, and from 
(B) the cerebellum of WT mice at 4, 9 and 14 weeks; IP: immunoprecipitation; WB: 
Western blot. Data representative of at least three independent experiments. 
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3.11 The sub-cellular distribution of SIRT1 is not altered in R6/2 mice 
Previous studies suggested that the phosphorylation of human SIRT1 can increase its 
nuclear localization and enzymatic activity (Nasrin et al., 2009).  To assess whether the 
mis-regulation of SIRT1 phosphorylation could affect its nuclear localization we 
prepared nuclear and cytoplasmic fractions from the striatum and cerebellum of R6/2 
and WT mice at 9 and 14 weeks of age. Notably, we did not detect any difference in 
the distribution of SIRT1 at any age between R6/2 and WT mice in either the striatum 
or cerebellum (Fig. 25 A and B). Interestingly, the level of SIRT1 in the nuclear fraction 
was more pronounced at 14 weeks as compared to 9 weeks of age in the striatum and 
cerebellum of both R6/2 and WT mice (Fig. 25 B). We went to analyse the 
phosphorylation level of SIRT1 in these two cellular compartments by 
immunoprecipitation, using nuclear and cytoplasmic extracts from the cerebellum. 
Interestingly, a strong phosphorylation signal was detected in the nuclear fraction of 
both R6/2 and WT samples and, as previously shown on total lysates, the level of 
phosphorylation was much higher in R6/2 as compared to WT mice (Fig 25 C). We tried 
to immunoprecipitate SIRT1 from striatal nuclear and cytoplasmic fractions but the 
amount of protein extracted resulted to be not enough to perform the 
immunoprecipitation. 
These results demonstrate that the sub-cellular distribution of SIRT1 is not affected by 
the presence of mHTT and suggest, once again, that the phosphorylation levels might 
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Figure 25. The sub-cellular distribution of SIRT1 is not altered in R6/2 mice.  (A) 
-tubulin and histone H3 of nucleo-cytoplasmic extracts from 
striatum and cerebellum of R6/2 and WT mice at 9 weeks of age. (B) Western blot for 
- tubulin and histone H3 of nucleo-cytoplasmic extracts from striatum and 
cerebellum of R6/2 and WT mice at 14 weeks of age. (C) Western blot of SIRT1 after 
SIRT1 immunoprecipitation from nuclear and cytoplasmic fractions extracted from 
cerebellum of R6/2 and WT mice at 9 weeks of age. IP: immunoprecipitation; WB: 
Western blot. Data representative of at least three independent experiments. 
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3.12 AMPK-α1 as regulator of SIRT1 affected by mHTT 
Previous studies showed that DBC1 (deleted in breast cancer 1) directly interacts with 
the catalytic domain of SIRT1 inhibiting its activity both in vitro and in vivo (Escande et 
al., 2010). This dynamic interaction is sensitive to the energetic state of the cell 
(Escande et al., 2010). Activation of AMP-activated protein kinase-α1 (AMPK-α1), an 
important cellular energy sensor in circumstances of low cellular energy, was recently 
shown to induce the activation of SIRT1 through its dissociation from DBC1 (Escande et 
al., 2012; Lau et al., 2014). To identify the possible role of AMPK-α1 and DBC1 in the 
molecular phenotypes described so far, we decided to study the interaction between 
these two opposing modulators of SIRT1 using co-immunoprecipitation. 
 We immunoprecipitated AMPK-α1 from the striatum and cerebellum, as well as 
half brain, of 9-week R6/2, 22-month HdhQ150 homozygous and aged-matched WT 
mice and detected the co-immunoprecipitated DBC1. Interestingly, we observed a 
stronger interaction between AMPK-α1 and DBC1 in the striatum of HD as compared 
to WT mice (Fig. 26 A), whereas equal amounts of DBC1 were co-immunoprecipitated 
with AMPK-α1 from cerebellar extracts of HD and WT samples (Fig 26 B). An increased 
interaction between AMPK-α1 and DBC1 was also observed in half brain lysates of HD 
as compare to WT mice (Fig 27). These data suggest two possible scenarios: either the 
increased interaction of AMPK-α1 with the SIRT1-DBC1 complex might promote SIRT1 
activation in the striatum of HD mice through the dissociation from DBC1, or the 
inability to induce SIRT1 in R6/2 mice might be due to an inhibitory retention of AMPK-
α1 via DBC1.  
 To gain insight into the molecular events characterising this process we 
examined the cellular distribution of AMPK-α1 and DBC1 in the striatum and 
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cerebellum of R6/2 and WT mice at 9 and 14 weeks of age by western blot of nucleo-
cytoplasmic extracts. Consistent with the phenotypes described so far, the striatum 
and cerebellum showed a different profile. Interestingly, we were able to detect DBC1 
in both cellular compartments and although at 9 weeks of age DBC1 was slightly more 
abundant in the striatal cytoplasmic fraction, this balance was reverted by 14 weeks of 
age for both R6/2 and WT mice (Fig. 26 C). In contrast cerebellar DBC1 levels remained 
constant between the two cellular compartments at 9 and 14 weeks of age for both 
R6/2 and WT mice (Fig. 26 D). Using immunostaining of nuclei isolated from the striata 
of R6/2 and WT mice at 4, 9 and 14 weeks of age we then monitored the distribution 
of AMPK-α1. At 9 weeks of age WT striatum showed signal of AMPK-α1 in the nucleus, 
whereas this did not occur in the striatum of R6/2 mice until 14 weeks of age (Fig. 26 
E). Conversely, cerebellar extracts showed an early nuclear accumulation of AMPK-α1 
in R6/2 at 9 weeks of age as compared to WT mice, where AMPK-α1 could only be 
detected in the nucleus at 14 weeks of age (Fig. 26 F). We confirmed these data by 
immunostaining for AMPK-α1 nuclei extracted from the cerebellum of R6/2 and WT 
mice at 4, 9 and 14 weeks of age (Fig. 26 E).  The nuclear accumulation of AMPK-α1 at 
9 weeks of age in the striatum of WT mice might indeed support a role for this kinase 
in the activation of SIRT1 a mechanism that appears to be compromised in the R6/2 
mice in which AMPK-α1 only reaches the nucleus at 14 weeks of age. Therefore, the 
increased interaction between AMPK-α1 and DBC1 might retain AMPK-α1 in the 
cytoplasm, inhibiting the activation of SIRT1, and/or attempt to rescue SIRT1 activity 
by preventing DBC1 from binding to SIRT1. Conversely, the early nuclear accumulation 
of AMPK-α1 in the cerebellum of R6/2 at 9 weeks of age as compared to WT mice 
might be an attempt to increase impaired SIRT1 activity. Taken together, these data 
Chapter 3                                                                   SIRT1 activity in HD mice 




suggest that the inhibition of SIRT1 function in the striatum of R6/2 might arises 
through an altered functionality of AMPK-α1 and that AMPK-α1 might be involved in 
rescuing a deficient SIRT1 function both in the striatum and cerebellum, although 
through different molecular mechanisms. 
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Figure 26. DBC1-AMPK-α1 interaction and their subcellular distribution in HD mice.  
(A-B) Western blots of DBC1 and AMPK-α1 after AMPK-α1 immunoprecipitation from 
(A) the striatum of 9-week R6/2 and 22-month HdhQ150 homozygotes, and (B) from 
the cerebellum of 9-week R6/2 and 22-month HdhQ150 homozygotes. (C-D) Western 
blot for DBC1, AMPK-α1, -tubulin and histone H3 of nucleo-cytoplasmic extracts from 
(C) striatum and (D) cerebellum of WT and R6/2 mice at 9 and 14 weeks of age. (E-F) 
Representative immunofluorescence image of nuclei extracted from (E) striatum and 
(F) cerebellum of WT and R6/2 mice at 4, 9 and 14 weeks of age immunostained for 
AMPK-α1 and counterstained with DAPI. Scale bar, 10 µm. IP, immunoprecipitation. 
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Figure 27. DBC1-AMPK-α1 interaction in mouse half brain. Western blot of DBC1 and 
AMPK-α1 after AMPK-α1 immunoprecipitation from half brain lysates of 9-week R6/2, 
22-month HdhQ150 homozygotes and age-matched WT mice. IP, 
immunoprecipitation. Hdh, HdhQ150 homozygotes. Data representative of at least 
three independent experiments. 
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3.13 SIRT1, AMPK-α1 and DBC1 as partners in the same regulatory circuit to 
control SIRT1 activity in the Striatum 
We observed an active role of AMPK-α1 in trying to rescue SIRT1 deficiency both in the 
striatum and cerebellum of R6/2 mice. To obtain further evidence of a regulatory 
circuit involving these three proteins we went to compare the expression levels of 
SIRT1, DBC1 and AMPK-α1 in the striatum and cerebellum of R6/2 at 4, 9 and 14 weeks 
of age, HdhQ150 homozygous at 2 and 22 months of age and age-matched control WT 
mice. Strikingly there was a synchronised significant down-regulation of all three genes 
at the mRNA level from 4 to 9 weeks of age in the striatum of WT mice (Fig. 28 A). 
Interestingly, we detected the same significant reduction in the striatum of R6/2 mice 
for Dbc1 and Ampk-α1, but this did not occur for Sirt1 (Fig. 28 A). Notably, the 
cerebellum of both WT and R6/2 mice did not show the same regulatory circuit as no 
coordinated changes in the expression levels of Sirt1, Dbc1 and Ampk-α1 were 
detected, although the expression level of Sirt1 was significantly higher in WT mice at 9 
and 14 weeks as compared to 4 weeks of age (Fig. 28 D). Protein analysis revealed 
steady-state levels of DBC1, consistent with the nucleo-cytoplasmic data, both in 
striatum and cerebellum of R6/2 and WT mice at all ages (Fig. 28 B, C, E and F). 
Interestingly, we observed a significant upregulation of AMPK-α1 in the striatum of WT 
mice at 9 and 14 weeks as compared to 4 weeks of age, which did not occur in the 
striatum of R6/2 mice (Fig. 28 B and C). Protein levels of AMPK-α1 were even and 
stable in the cerebellum of WT and R6/2 mice at all ages under analysis (Fig. 28 E and 
F). When we analysed SIRT1 protein level we detect no change in striatum with age, 
(Fig. 28 B and C) and a significant downregulation in the cerebellum of WT and R6/2 at 
14 weeks as compared to 4 weeks of age (Fig. 28 E and F). Interestingly, HdhQ150 
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homozygous mice showed no difference in the protein levels of SIRT1, DBC1 and 
AMPK-α1 at 2 and 22 months of age as compared to WT mice (Fig. 29 A and B). Taken 
together these data show the presence of an age-related downregulation of Sirt1, 
Dbc1 and Ampk-α1 taking place between 4 and 9 weeks of age in the striatum of WT 
mice, which is maintained in the striatum of R6/2 mice only for Dbc1 and Ampk-α1, but 
not for Sirt1. This might suggest that in WT mice a negative feedback mechanism 
responds to SIRT1 activation and as SIRT1 activity is not induced in the striatum of R6/2 
mice such a feedback mechanism is not instigated. Furthermore, the increased levels 
of AMPK-α1 in WT striatum at 9 and 14 weeks of age may also suggest that this protein 
has become stabilised and that this does not happen in R6/2 mice, contributing to the 
mis-regulation of SIRT1 (Fig. 54A). 
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Figure 28. RNA and protein analysis of SIRT1, DBC1 and AMPK-α1 in R6/2 mice. qPCR 
analysis of the expression level of Sirt1, Dbc1 and Ampk-1 in (A) striatum and (D) 
cerebellum of R6/2 and WT mice at 4, 9 and 14 weeks of age. Values were calculated 
relative to 4-week WT mice. Relative protein level of SIRT1, DBC1 and AMPK-α1 in (B) 
striatum and (E) cerebellum of R6/2 and WT mice at 4, 9 and 14 weeks of age. 
Densitometric values were calculated relative to 4-week WT mice. Representative 
western blots for SIRT1, AMPK-α1 and DBC1 in (C) striatum and (F) cerebellum of R6/2 
and WT mice at 4, 9 and 14 weeks of age. Data are the mean ± SEM. * p<0.05; ** 
p<0.01; *** p<0.001: statistically significant difference as compared to WT at 4 weeks 
of age. # p<0.05; ### p<0.001: statistically significant difference between WT and R6/2. 
For qPCR n=8 / genotype, for WB n=4 / genotype. 
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Figure 29. Protein analysis of SIRT1, DBC1 and AMPK-1 in HdhQ150 homozygous  
mice. (A) Relative protein levels and (B) representative western blots of SIRT1, DBC1 
and AMPK-α1 in striatum and cerebellum of 2 and 22-month HdhQ150 homozygotes 
and WT mice. Densitometric values were calculated relative to 2-month WT mice. Data 
are mean ± SEM. Hdh, HdhQ150 homozygotes. n=4 / genotype. 
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3.14 General comments 
In this work, we explore the impact of HD pathology on SIRT1 function in the brain. We 
provide evidence for a considerable down-regulation of SIRT1 activity in the brain of  
two well-characterized HD mouse models: R6/2 and HdhQ150 mice.  
These models are used in various preclinical studies because of their particular 
strengths in genetic and phenotypic characteristics. The mHTT fragment transgenic 
models exhibit early-onset and rapidly progressing behavioural and neuropathological 
phenotypes associated with significant weight loss and premature death. The 
advantage of the Knock-in is that they may better resemble the pathogenic 
mechanisms that occur in the patients (Gusella and MacDonald, 2006; Van Raamsdonk 
et al., 2007). Moreover, since the HdhQ150 mice do not contain human sequence but 
they express 100% of the mHTT derived from the mouse Htt gene, they are the most 
precise genetic model of HD and hence are valuable to study molecular mechanisms 
and therapeutic interventions requiring such precise level of mutant Hdh expression in 
the endogenous genomic context.  
Mouse models of HD share many features but, at the same time, they show many 
discrepancies. A critical question is which mouse model or models should be used in a 
preclinical study of a therapeutic candidate. An ideal HD mouse model should have: 
1. a genetic construct that is similar if not identical to the patients; 
2. robust behavioural deficits and selective neuropathology mimicking the 
patients; 
3. these phenotypes are early onset, rapidly progressing, easily quantifiable, and 
have limited variability between mice.  
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From our description of the preclinical HD mouse models, it is apparent that each of 
the current models only partially satisfies such requirements. The fragment models 
(i.e., R6/2) have very rapid onset and progression of disease, as well as low phenotypic 
variability (10–20 per treatment group in preclinical trials); weight loss and early 
lethality in these models can be used as surrogate markers of disease. However, there 
are also some concerns with the use of mHTT fragment models to determine the 
preclinical efficacy of therapeutic candidates. First, the neuropathology in the 
fragment models is more widespread and relatively non-selective. Second, because the 
disease progression in patients is usually very slow, another concern is that a potential 
efficacious therapeutic mechanism or candidate in human HD may not be effective in 
the fragment model. Third, the fragment models only express a small portion of mHTT 
regulatory elements and proteins; thus, the study of HD in the contest of Fl-HTT cannot 
be performed. 
The availability of several Knock-in mouse models provides new opportunities to test 
HD preclinical candidates in model systems that have genetic, genomic, and protein 
context more similar to human HD; moreover, they have a slowly progressing disease 
process that may be more closely related to the process in the human disease; and 
also they have neuropathology that is selective to the striatum and cortex. However, 
the main concern in the use of the full-length models in preclinical trials is cost. 
Because the length of the trial in these mice is very long (i.e., up to 1–2 years in Knock-
in mice) and the variability of their outcomes is very high, which may require a larger 
number of mice for each study, to work with these mice can result very expensive. 
It is clear that both the mHTT fragment models and the full-length models have their 
potential strengths and weaknesses in the preclinical studies. A good idea could be to 
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perform a screening assay in a fragment mouse model of HD. R6/2 mice may be a 
preferred model for this purpose because of the model’s rapid disease course. Such a 
therapeutic screen, with primary outcomes focusing on behavioural and 
neuroprotection, can provide relatively rapid information on the potential therapeutic 
efficacy of a large number of preclinical candidates at a reasonable cost. After 
demonstrating therapeutic efficacy in the fragment model, the clinical study should be 
performed in a full-length model. At this point, if the compound has proven safety in 
humans and/or is already in clinical use, direct clinical study in HD patients may be 
warranted.  
We should also consider that the R6/2 show a very aggressive phenotype and this 
could mask a positive effect of a clinical trial. For this reason, a different approach 
could be to perform a study in both HD mouse models at the same time.  
In this work, we performed a parallel study in N-terminal transgenic and Knock-in 
mouse models.   
 The data presented so far provide evidence of a progressive impairment in SIRT1 
activity in HD mice. P53 has been shown to be located in the nucleus and it is one of 
the main substrate of SIRT1. We used an immunohistochemistry on isolated nuclei to 
measure the deacetylation of P53 by SIRT1. The advantage of this technique is to focus 
only on the nuclear fraction keeping away any cytoplasmic contamination. Moreover, 
this is the first technique to date to be able to detect specifically SIRT1 activity in 
mouse tissues.  On another hand, this method does not allow to distinguish among all 
the cellular populations present in the brain. This limit could be overcome performing 
a double staining with marker that can recognize a specific cell population (but 
unfortunately we do not have specific marker for all kind of cell populations) or 
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performing a sorting of all the cell populations of the brain but a cell sorting will never 
provide an adequate number of cells to perform an immunohistochemistry.  
 The data presented so far provide evidence of a progressive impairment in SIRT1 
activity in HD mice. We showed that the impairment of SIRT1 function is not related to 
a sequestration of SIRT1 protein into mHTT inclusions. To confirm these data, we 
performed a western blot from HD and WT brain lysates and did not detect a reduction 
in SIRT1 protein levels in HD mouse models as compared to WT.  
 These data suggest that mHTT acts through other mechanisms to control SIRT1 
activity. Several studies have shown that SIRT1 activity is mainly regulated by post-
translational modification such as phosphorylation (Sasaki et al., 2008). Therefore, to 
understand the effect of mHTT on SIRT1 function, we monitored the phosphorylation 
status of SIRT1 in HD mice. The immunoprecipitation of SIRT1 data, representative of 
at least three independent experiments, from half brains and brain regions of R6/2 and 
HdhQ150 homozygous mice revealed that the phosphorylation status of SIRT1 is 
altered in HD mouse models. This indicates that the impairment of SIRT1 function in 
the brain of HD mice might be related to an altered phosphorylation profile. 
Interestingly, the levels of phosphorylated SIRT1 remain unchanged in the cortex with 
age. However, we found an opposing pattern of phosphorylation between the striatum 
and cerebellum; surprisingly, we detected a reduction of phosphorylated SIRT1 in the 
striatum both R6/2 (9 weeks) and HdhQ150 homozygous (22 months) mice compared 
to WT, while phosphorylated SIRT1 was increased in the cerebellum of both HD mouse 
models. These data further confirm that the status of SIRT1 phosphorylation is altered 
in presence of mHTT and with disease progression. The Mpm2 antibody provides 
information about the different phosphorylation profile of SIRT1 between WT and HD 
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mice but it does not specify which SIRT1 residue is characterized by an alteration of the 
phosphorylation status in HD mouse model. Other techniques can be used to 
overcome the limit showed by the MpM2 antibody. For example, a mass spectrometry 
analysis could detect homologies and differences in the phosphorylation of SIRT1 
residues between WT and HD mice and it could be really useful to understand which 
residues have an altered phosphorylation profile in presence of mHTT. 
 To investigate whether the altered pattern of SIRT1 phosphorylation in striatum 
and cerebellum of HD mice was related to an impairment of SIRT1 function, we 
monitored acetylation status of P53 by immunohistochemistry on isolated nuclei from 
both these brain regions of R6/2 and WT mice. Interestingly, we detected a robust 
reduction in the level of AcP53 in the striatum of WT mice from 4 to 14 weeks of age, 
consistent with an increase in SIRT1 activity. We did not detect the same increase in 
the striatum of R6/2 mice. We did not find any change in the acetylation status of P53 
in the cerebellum in WT mice, but we found a significant increase in AcP53 in R6/2 
cerebella from 4 to 14 weeks of age, corresponding to a progressive impairment in 
SIRT1 activity. This is one of the most important experiments performed so far. Indeed, 
this experiment confirms that: 
1. the impairment in SIRT1 activity happens in conjunction with an alteration in the 
SIRT1 phosphorylation status.  
2. the mechanism that control SIRT1 function in physiological condition is different 
in different brain regions. 
3. the mechanism underlying the impairment in SIRT1 function is different in 
different brain regions. This can explain why we found a different alteration of 
SIRT1 phosphorylation in different brain regions. Indeed, in physiological 
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condition SIRT1 activity is induced in the striatum between 4 and 9 weeks, 
whereas it remains constant in the cerebellum. The presence of mHTT can 
block this induction process in the striatum (Fig.53 A) and cause a reduction in 
normal SIRT1 function in the cerebellum resulting in an impairment of SIRT1 
activity in both brain regions. 
The induction of SIRT1 activity in the striatum and the unchanged level of SIRT1 
function in the cerebellum of WT mice with age led us to monitor the phosphorylation 
status of SIRT1 in both brain regions from WT mice. The immunoprecipitation of SIRT1 
from WT mice at 4, 9 and 14 weeks revealed a change in the phosphorylation status of 
SIRT1 in the striatum with age, suggesting that in the striatum, a change in the 
phosphorylation status of SIRT1 can be related to an induction of SIRT1 activity. The 
cerebellum showed a constant phosphorylation status of SIRT1 in WT mice with age, 
consistent with a lack of a change in SIRT1 activity. 
 To check if the miss-regulation of SIRT1 phosphorylation could affect its nuclear 
localisation, we prepared nuclear-cytoplasmic fractions from the striatum and 
cerebellum of R6/2 and WT mice at 9 and 14 weeks of age. Interestingly, we did not 
detect any difference in the distribution of SIRT1 between R6/2 and WT mice in both 
striatum and cerebellum at any age. 
 It has been shown that DBC1 can interact, in vitro and in vivo, with the catalytic 
domain of SIRT1 (Escande et al., 2010) and inhibit its activity (Zhao et al., 2008). In 
contrast AMPK-α1 is a positive regulator of SIRT1. Indeed, AMPK-α1 is an important 
cellular energy sensor that in circumstances of low cellular energy can induce the 
activation of SIRT1 through the dissociation from DBC1 (Escande et al., 2012; Lau et al., 
2014). We analysed the interaction between these two opposing modulators of SIRT1 
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in the context of HD pathogenesis. AMPK-α1 immunoprecipitation from the striatum 
and cerebellum of R6/2 (9 weeks) and HdhQ150 homozygous (22 months) mice 
showed that the interaction between AMPK-α1 and DBC1 in the striatum of HD mice 
was increased as compared to WT mice, whereas there was no difference in this 
interaction in the cerebellum. The increased interaction between DBC1 and AMPK-α1 
could be interpreted a follow: 
1. the increased interaction of AMPK-α1 with the SIRT1-DBC1 complex might 
promote SIRT1 activation in the striatum of HD mice through the dissociation 
from DBC1 
2. the inability to induce SIRT1 in R6/2 mice might be due to an inhibitory retention 
of AMPK-α1 via DBC1.  
 At the same time, we monitored the sub-cellular distribution of DBC1 and AMPK-
α1 using nucleo-cytoplasmic preparations from R6/2 striatum and cerebellum at 9 and 
14 weeks of age. This was complemented with immunohistochemistry for AMPK-α1 on 
isolated nuclei extracted from R6/2 and WT mice striatum and cerebellum at 4, 9 and 
14 weeks of age. DBC1 was found more concentrated in the cytoplasmic than the 
nuclear fraction at 9 weeks of age. This balance reverted at 14 weeks of age in both 
R6/2 and WT mice. In contrast, the level of DBC1 was constant between the two 
cellular compartments in the cerebellum at 9 and 14 weeks of age in both R6/2 and 
WT mice. The immunohistochemistry on isolated nuclei extracted from R6/2 and WT 
mice showed that AMPK-α1 was present in the nuclei of WT striatum at 9 weeks of 
age, whereas it was not detected in the striatum of R6/2 mice until 14 weeks of age. 
Conversely, cerebellar extracts showed an early nuclear accumulation of AMPK-α1 in 
R6/2 at 9 weeks of age as compared to WT mice, where AMPK-α1 could be detected in 
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the nucleus only at 14 weeks of age. The delayed accumulation of AMPK-α1 in striatal 
nuclei of R6/2 mice might be caused by its retention by DBC1 in the cytoplasm and this 
can impede SIRT1 activation (Fig. 53 A), whereas AMPK-α1 nuclear accumulation in the 
cerebellum of R6/2 mice was anticipated by 9 weeks of age, maybe trying to reduce 
the SIRT1 inhibition dictated by mHTT. Whether DBC1 was involved in a cytoplasmic 
retention of AMPK-α1 could be further confirmed performing the same experiments in 
tissues Dbc1-/-::R6/2 but unfortunately we didn’t have time to do it. 
 Analysis of mRNA expression showed that Sirt1, Dbc1 and Ampk-α1 are 
downregulated in WT striatum from 4 to 14 weeks of age. Interestingly, we detected 
the same significant reduction in the striatum of R6/2 mice for Dbc1 and Ampk-α1, but 
this did not occur for Sirt1.  The levels of these three genes were not downregulated in 
the cerebellum of WT and R6/2 mice.  We observed no change in the protein level of 
SIRT1 and DBC1 in the striatum of WT and R6/2 mice at 9 and 14 weeks of age as 
compared to 4 weeks. There was a significant upregulation of AMPK-α1 in the striatum 
of WT mice at 9 and 14 weeks as compared to 4 weeks of age, which did not occur in 
the striatum of R6/2 mice. The protein levels of DBC1 and AMPK-α1 were stable in the 
cerebellum of WT and R6/2 mice at all ages under analysis.  
However, there was a significant downregulation of SIRT1 in the cerebellum of WT and 
R6/2 at 14 weeks as compared to 4 weeks of age. Interestingly, HdhQ150 homozygous 
mice showed no difference in the protein levels of SIRT1, DBC1 and AMPK-α1 at 2 and 
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RESULTS: EFFECT OF Dbc1 ABLATION ON HD PHENOTYPE 
4.1 Dbc1 knock-out mice characterization 
Dbc1 knock-out (Dbc1-/-) mice were generated by targeted insertion of a neomycin 
resistance gene between exon 6 and exon 7 of the Dbc1 gene (geneID 219158) 
(Escande et al., 2012) (Fig. 30). The insertion introduced a stop codon that results in 
the nonsense-mediated decay of the Dbc1 mRNA. The Dbc1 gene was targeted in an 
embryonic stem cell line (XN876) and the ES cells were injected into C57BL/6 
blastocysts to generate chimeric mice. Chimeras were then backcrossed with C57BL/6 
mice to generate Dbc1 heterozygous (Dbc1+/-) mice, which were used for subsequent 
breeding. However, the specific position, length and sequence of the insertion are 
unknown. To confirm the insertion that disrupted the Dbc1 gene in Dbc1-/- mice, 
genotyping primers (Table 6) were used to obtain a DNA fragment that contained a 
part of the Dbc1 gene and part of the insertion.   
 
 
Figure 30. Exon-Inton structure of the Dbc1 gene in mouse. Insertion of the NEO 
cassette between the exon 6 and exon 7. Positions of PCR primers are shown.  





To investigate how the insertion in the Dbc1 gene affects Dbc1 expression, RNA was 
extracted and cDNA synthesised from cortex of WT, Dbc1+/- and Dbc1-/- mice at 4 weeks 
of age. Levels of Dbc1 mRNA were measured by real-time qPCR. As expected, genetic 
ablation in Dbc1 resulted in a significant decrease of Dbc1 mRNA levels in Dbc1+/- and 
Dbc1-/- as compared to WT mice (Fig. 31 A). Dbc1+/-  and Dbc1-/-  mice were found to 
express 70% and 20% of Dbc1 mRNA as compared to WT levels respectively. Levels of 
DBC1 protein were measured by western blotting of cortical lysates from WT, Dbc1+/- 
and Dbc1-/- mice at 4 weeks of age using DBC1 antibody produced by Bethyl 
laboratories (DBC1/p30 antibody A300-432A). This antibody is able to recognise the 
epitope A300-432A that is encoded by a gene sequence between exon 9 and exon 12, 
which should be absent in Dbc1-/- mice. Dbc1+/- and Dbc1-/- mice were found to express 
60% and 15% of DBC1 protein as compared to WT mice respectively (Fig. 31 B and C), 
indicating that a very low percentage of DBC1 protein is still expressed in Dbc1-/- mice.  
  








   
 
 
Figure 31. DBC1 mRNA and protein levels in 4 week old cortex from WT, Dbc1+/- 
(Dbc1 heterozygous)  and Dbc1-/- (Dbc1 knock-out) mice. (A) Dbc1 mRNA levels in 4 
week old cortex from WT, Dbc1+/- and Dbc1-/- mice. Expression levels were normalised 
to the housekeeping genes Atp5b, Canx and Rlp13a (Fig.33) and expressed as fold 
change of WT levels ± SEM. n=8/ genotype. (B) Relative DBC1 protein levels and (C) 
representative western blots of WT, Dbc1+/- and Dbc1-/- lysates 4 week old from cortical 
mice. Values were normalised to β-actin and expressed as fold change of WT ± SEM. 
n=4/ genotype. (D) Western blots of DBC1 after DBC1 immunoprecipitation from 
cortex of WT and Dbc1-/- mice (KO) at 4 weeks of age. ***P<0.001 statistically 
significant as compared to WT. IP: immunoprecipitation. 
  





Unlike the result obtained by western blot, DBC1 immunoprecipitation (Fig. 31 D) and 
DBC1 immunostaning on isolated nuclei (Fig. 32 A) did not reveal a DBC1 signal in 
Dbc1-/- mice. Taken together, these results may suggest that the DBC1 antibody has a 
greater affinity for the A300-432A epitope when the DBC1 protein is denatured. 
Furthermore, the low percentage of the DBC1 protein in Dbc1-/- mice indicates that the 
mechanism used to induce the ablation of DBC1 in these mice is leaking. Since, the 
NEO cassette is located in an intron it could be possibly removed during splicing, 
promoting the transcription of the full-length gene and the translation of DBC1 
protein.  
4.1.1 Dbc1 knock-out mice show a robust increase of SIRT1 activity in the brain  
A previous study has suggested that DBC1 protein is a negative regulator of SIRT1 
activity (Kim et al., 2008). To examine the role of DBC1 in the control of SIRT1 activity, 
we investigated whether DBC1 regulates SIRT1 function in vivo. We examined the 
effect of DBC1 down-regulation on endogenous SIRT1 deacetylase activity by 
monitoring the levels of endogenous P53 acetylation. To confirm the release of the 
inhibitory effect of DBC1 on SIRT1 we immunostained nuclei extracted from half brains 
of WT, Dbc1+/- and Dbc1-/- mice at 4 weeks of age for DBC1, P53, AcP53 and SIRT1 and 
counterstained with DAPI. Notably, the absence of DBC1 did not affect the level and 
nuclear accumulation of SIRT1 and/or P53 (Fig. 32 A and B). As expected, the ablation 
of DBC1 resulted in an increase of SIRT1 activity as reported by significant reduction in 
signal intensity for AcP53 in Dbc1+/- (≈50%) and Dbc1-/- (≈90%) mice as compared to WT 
mice (Fig. 32 A and B). 
  








Figure 32. SIRT1 activity levels in 4 week old cortex from WT, Dbc1+/- (Dbc1 
heterozygous) and Dbc1-/- (Dbc1 knock-out) mice. (A) Representative 
immunofluorescence image of nuclei extracted from half brains of WT, Dbc1+/- and 
Dbc1-/- mice at 4 weeks of age immunostained  for DBC1, P53, AcP53 and SIRT1, and 
counterstained with DAPI. (B) Relative intensity level of DBC1, P53, AcP53 and SIRT1 
immunostaning in A. The quantification indicates that the level of acetylated p53 is 
lower in Dbc1+/- and Dbc1-/- mice, consistent with an increase in SIRT1 activity. Scale 
bar: 10 µm. Data are mean ±SEM. ***p<0.001 statistically significant as compared to 
WT. n=4 / genotype. 
  





4.1.2 Effect of Dbc1 Ablation on Sirtuins and Hdacs gene expression in the brain 
regions 
To demonstrate that the ablation of Dbc1 increases SIRT1 activity without affecting its 
expression level, we performed real-time qPCR and western blotting on cortex from 
WT, Dbc1+/- and Dbc1-/- mice at 4 week of age. We observed that the genetic reduction 







Figure 33. SIRT1 mRNA and protein levels in 4 week old cortex from WT and Dbc1-/- 
(Dbc1 knock-out) mice. (A) Sirt1 mRNA levels in 4 week old cortex from WT, Dbc1+/- 
and Dbc1-/- mice. Expression levels were normalised to the housekeeping genes Atp5b, 
Canx and Rlp13a (Fig. 33) and expressed as fold change of WT levels ± SEM. n=8 / 
genotype. (B) Relative SIRT1 protein levels and (C) representative western blots of WT, 
Dbc1+/- and Dbc1-/- cortex lysates 4 week old. Values were normalised to β-actin and 
expressed as fold change of WT ± SEM. n=4 / genotype.  
  





Subsequently, to ascertain that the reduction or depletion of Dbc1 does not affect the 
mRNA expression of the other Hdacs or Sirtuins, we performed real-time qPCR in five 
brain regions of WT, Dbc1+/- and Dbc1-/- mice at 4 week of age. As expected, genetic 
ablation of Dbc1 resulted in a significant decrease in Dbc1 mRNA levels in all five brain 
regions of Dbc1+/- and Dbc1-/- as compared to WT mice. Notably, we did not detect any 
significant changes in the gene expression levels of all Sirtuins and Hdacs among the 
three different genotypes (Fig. 34, 35, 36, 37 and 38). 
  








Figure 34. Sirtuin (1-7) and Hdac (1-11) mRNA levels in 4 week old cortex from WT, 
Dbc1+/- and Dbc1-/- mice. Expression levels were normalised to the housekeeping genes 
Atp5b, Canx and Rlp13a and expressed as fold change of WT levels ± SEM. n = 8 / 
genotype. 
  







Figure 35. Sirtuin (1-7) and Hdac (1-11) mRNA levels in 4 week old stritum from WT, 
Dbc1+/- and Dbc1-/- mice. Expression levels were normalised to the housekeeping genes 
Atp5b, Ywhaz and Ubc and expressed as fold change of WT levels ± SEM. n = 8 / 
genotype. 







Figure 36. Sirtuin (1-7) and Hdac (1-11) mRNA levels in 4 week old cerebellum from 
WT, Dbc1+/- and Dbc1-/- mice. Expression levels were normalised to the housekeeping 
genes Atp5b, Rlp13a and Eif4a2 and expressed as fold change of WT levels ± SEM. n = 8 
/ genotype. 







Figure 37. Sirtuin (1-7) and Hdac (1-11) mRNA levels in 4 week old hippocampus from 
WT, Dbc1+/- and Dbc1-/- mice. Expression levels were normalised to the housekeeping 
genes Atp5b, Ubc and Gapdh and expressed as fold change of WT levels ± SEM. n = 8 / 
genotype. 







Figure 38. Sirtuin (1-7) and Hdac (1-11) mRNA levels in 4 week old brain stem from 
WT, Dbc1+/- and Dbc1-/- mice. Expression levels were normalised to the housekeeping 
genes Atp5b, Ubc and Gapdh and expressed as fold change of WT levels ± SEM. n = 8 / 
genotype. 





4.2 Dbc1 ablation does not improve HD-related phenotypes 
The data presented so far indicate that SIRT1 function is altered in the brain of HD 
mice caused by the impairment of different cellular processes in specific brain regions. 
The phosphorylation status of SIRT1 is altered and we hypothesise that AMPK-1 acts 
to rescue SIRT1 function. As DBC1 is a negative regulator of SIRT1 we decided to use a 
genetic approach to reduce DBC1 levels in R6/2 mice and investigate whether the 
dissociation between SIRT1 and DBC1 could increase striatal SIRT1 activity and improve 
HD phenotypes. We crossed R6/2 transgenic mice with Dbc1 knock-out mice to obtain 
double transgenic mice (Dbc1-/-::R6/2) (Fig. 39 and Table 7).  
 
 
Figure 39.  Breeding scheme used to reduce Dbc1 levels in R6/2 mice. 
 
 
Genotype WT Dbc1+/- Dbc1-/- R6/2 Dbc1+/-::R6/2 Dbc1-/-:: R6/2 
Males 7 11 9 13 9 6 
Females 15 8 9 9 9 13 
Total 22 19 18 22 18 19 
 
Table 7.  Number of mice used in the phenotyping study. 
  





R6/2 mice develop behavioural abnormalities such as rotarod, grip strength 
impairments, hypo-activity and deficiencies in learning and memory tasks by 8 weeks 
of age (Hockly et al., 2003). A concomitant loss of body and brain weight, as well as 
atrophy of skeletal muscle is also evident (Mangiarini et al., 1996).  
The behavioural study was as follows: 
 Body weight measured weekly from 4 until 14 weeks of age.  
 Grip strength measured in mice at 4 weeks of age and then bi-weekly from 7 to 
13 weeks of age.  
 Rotarod performance was assessed at 4 weeks of age and then bi-weekly from 
6 to 14 weeks. 
 Spontaneous motor activity was measured bi-weekly from 5 to 13 weeks of 
age.  
Mice were sacrificed at 15 weeks of age and the brains were weighed. 
  





4.2.1 Dbc1 ablation does not rescue SIRT1 activity in R6/2 mice 
To confirm an increase of SIRT1 activity in the absence of DBC1, we immunostained 
nuclei extracted from half brains of WT, Dbc1-/-, R6/2 and Dbc1-/-::R6/2 mice at 9 weeks 
of age for SIRT1, P53, AcP53 and DBC1 and counterstained with DAPI. Notably, the 
absence of DBC1 did not affect the level and nuclear accumulation of SIRT1 and/or P53 
(Fig. 41 A and B). As expected, the ablation of DBC1 in WT mice resulted in an increase 
of SIRT1 activity as reported by a significant reduction (≈65%) in signal intensity for 
AcP53 in Dbc1-/- as compared to WT mice. R6/2 mice showed a significantly higher 
level of AcP53 compared to WT samples, consistent with a decrease of SIRT1 activity 
(Fig. 41 A and B). Surprisingly, Dbc1-/-::R6/2 mice showed the same SIRT1 impairment 
as R6/2 mice and the level of AcP53 was significantly higher than in WT mice (Fig. 41 A 
and B). Levels of Dbc1 and R6/2 transgene have been confirmed by qPCR (Fig. 40). 
Taken together, these results suggest that the negative effect of mHTT on SIRT1 
activity might be multifactorial and/or operate outside the inhibitory circuit controlled 
by DBC1. In line with these results, we did not detect any effect on the onset and 
progression of several behavioural and pathological HD-related phenotypes such as 
brain weight, body weight, grip strength, rotarod and activity (Fig. 42, 43, 44, 45, 46, 
47, 48 and 49). 
  








Figure 40. The mRNA expression levels of Dbc1 and R6/2 transgene in 9 week old 
cortex from WT, Dbc1-/-, R6/2 and Dbc1-/-::R6/2 mice. Expression levels were 
normalised to the housekeeping genes Atp5b and Rlp13a and expressed as fold change 
of WT levels ± SEM. n = 8 / genotype.  
 
  








Figure 41. SIRT1 activity in 9 week half brain of WT, Dbc1-/- (Dbc1 knock-out), R6/2 
and Dbc1-/-::R6/2 (Double transgenic) mice. (A) Representative immunofluorescence 
image of nuclei extracted from half brains of WT, Dbc1-/-, R6/2 and Dbc1-/-::R6/2 mice 
at 9 weeks of age immunostained  for SIRT1, AcP53, P53 and DBC1 and counterstained 
with DAPI. (B) Relative intensity level of SIRT1, AcP53, P53 and DBC1 immunostaning in 
A. The quantification indicates that the level of acetylated P53 is lower in Dbc1-/- mice 
and higher in R6/2 as compared to WT, consistent with an increase and a decrease in 
SIRT1 activity, respectively. Scale bar: 10 µm. Data are mean ± SEM. ***p<0.001 
statistically significant as compared to WT. n=4 / genotype. 
 
  





4.2.2 DBC1 reduction does not improve the weight loss in R6/2 mice 
Mice were weighed weekly from 4 until 14 weeks of age. As the gender significantly 
affected the weight (p<0.0005) and weight gain (p<0.0005), male and female weights 
were depicted separately (Fig. 42 and 43). R6/2 mice weighed significantly less than 
WT mice (p<0.0005) overall.  Weight loss in R6/2 transgenic mice started at 11 weeks 
of age (p=0.05) and increased with disease progression (p<0.0005). The Dbc1 mutation 
had no overall effect on R6/2 weight loss (p=0.754) or on the decrease in the weight of 





Figure 42. Effect of Dbc1 knock-down and knock-out on body weight loss in R6/2 
males mice. Mean body weight measured from 4 until 14 weeks of age in WT (22), 
Dbc1+/- (19), Dbc1-/- (18), R6/2 (22), Dbc1+/-::R6/2 (18) and Dbc1-/-::R6/2  (19) mice. 






Figure 43. Effect of Dbc1 knock-down and knock-out on body weight loss in R6/2 
females mice. Mean body weight measured from 4 until 14 weeks of age in WT (22), 












Table 8. Summary of p-values obtained from the statistical analysis of body weight 









4.2.3 Grip strength is not improved by the loss of DBC1 in R6/2 mice 
Grip strength was measured in mice at 4 weeks of age and bi-weekly from 7 to 13 
weeks of age. As there was a significant gender difference in over all grip strength 
performance (p<0.0005), the average grip strength of male and female mice is 
presented separately (Fig. 44 and 45). R6/2 mice had reduced grip strength compared 
to WT (p<0.0005). This deficit was apparent by 11 weeks of age (p<0.0005) and 
deteriorated over the time (p<0.0005). The Dbc1 mutation had no overall effect on 





Figure 44. Effect of Dbc1 knock-down and knock-out on grip strength performance in 
R6/2 females mice. Grip strength performance measured at 4 week and bi-weekly 
from 7 to 13 weeks of age in WT (22), Dbc1+/- (19), Dbc1-/- (18), R6/2 (22), Dbc1+/-::R6/2 
(18) and Dbc1-/-::R6/2  (19) mice. Error bars represent ± SEM. 
 







Figure 45. Effect of Dbc1 knock-down and knock-out on grip strength performance in 
R6/2 females mice. Grip strength performance measured at 4 week and bi-weekly 
from 7 to 13 weeks of age in WT (22), Dbc1+/- (19), Dbc1-/- (18), R6/2 (22), Dbc1+/-::R6/2 













Table 9. Summary of p-values obtained from the statistical analysis of grip strenght 









4.2.4 Rotarod performance is not improved by the ablation of Dbc1 gene in R6/2 
mice 
Rotarod performance was assessed at 4 weeks of age and measured bi-weekly from 6 
to 14 weeks of age. No gender effects were observed (p=0.236). R6/2 mice were 
indistinguishable from WT littermates at 4 weeks of age (p=0.462) but their 
performance deteriorated over time (p<0.0005) starting at 8 weeks of age (p<0.0005). 
Dbc1+/- and Dbc1-/- mice did not perform differently from WT mice overall (p=0.584) or 
with time (p=0.384) and down-regulation or ablation of Dbc1 had no effect on the 
rotarod performance of R6/2 mice (p=0.265) or its deterioration over the time 
(p=0.692) (Table 10). Therefore, it was concluded that neither DBC1 reduction nor 




Figure 46.  Dbc1 knock-down and knock-out does not improve rotarod performance 
in R6/2 mice. Rotarod performance measured at 4 week and bi-weekly from 6 to 14 
weeks of age in WT (22), Dbc1+/- (19), Dbc1-/- (18), R6/2 (22), Dbc1+/-::R6/2 (18) and 
Dbc1-/-::R6/2  (19) mice. Error bars represent ± SEM. 
 
 













Table 10. Summary of p-values obtained from the statistical analysis of rotarod 
performance measurements. Statistical analysis was performed by ANOVA-General 
Linear Model repeated measures. 
  





4.2.5 Dbc1 genetic reduction does not influence hypo-activity of R6/2 mice 
Spontaneous motor activity was recorded for each mouse for 30 min bi-weekly from 5 
to 13 weeks of age. R6/2 mice exhibited significant hypo-activity with disease 
progression compared to wild type mice for all four parameters. Deficits in MOBILITY 
were already apparent in R6/2 transgenic mice at 5 weeks of age. HYPO-ACTIVITY 
became evident in R6/2 transgenic mice at 7 weeks of age. Decreased CENTRE 
REARING and REARING was detected at 9 and 11 weeks of age respectively. Reduction 
or ablation of DBC1 had no effect on any of these parameters at any age tested, and 
therefore did not modify the pattern of exploration over time and did not affect the 
hypo-activity of R6/2 mice (Fig. 47, 48, 49  and 50). 
  







Figure 47. Spontaneous motor activity in R6/2 males. Activity and mobility were 
recorded in mice over the course of 30 min at 5, 7, 9, 11 and 13 weeks of age. 
Spontaneous motor activity parameter measurements were visualised by plotting 5 
min moving averages.  







Figure 48. Spontaneous motor activity in R6/2 males. Rearing and centre rearing were 
recorded in mice over the course of 30 min at 5, 7, 9, 11 and 13 weeks of age. 
Spontaneous motor activity parameter measurements were visualised by plotting 5 
min moving averages. 







Figure 49. Spontaneous motor activity in R6/2 females. Activity and mobility were 
recorded in mice over the course of 30 min at 5, 7, 9, 11 and 13 weeks of age. 
Spontaneous motor activity parameter measurements were visualised by plotting 5 
min moving averages.  







Figure 50. Spontaneous motor activity in R6/2 females. Rearing and centre rearing 
were recorded in mice over the course of 30 min at 5, 7, 9, 11 and 13 weeks of age. 
Spontaneous motor activity parameter measurements were visualised by plotting 5 
min moving averages.  









5 =0.547 <0.001 =0.469 =0.642 
7 <0.001 <0.001 =0.358 =0.328 
9 <0.001 <0.001 <0.001 =0.219 
11 <0.001 <0.001 <0.001 <0.001 




5 =0.643 =0.144 =0.664 =0.864 
7 =0.479 =0.241 =0.129 =0.267 
9 =0.246 =0.185 =0.678 =0.367 
11 =0.531 =0.598 =0.254 =0.120 




5 =0.380 =0.468 =0.498 =0.852 
7 =0.168 =0.216 =0.271 =0.216 
9 =0.243 =0.375 =0.117 =0.579 
11 =0.098 =0.598 =0.663 =0.865 




5 =0.284 <0.001 =0.306 =0.845 
7 <0.001 <0.001 =0.097 =0.386 
9 <0.001 <0.001 <0.001 =0.124 
11 <0.001 <0.001 <0.001 <0.001 




5 =0.194 =0.846 =0.868 =0.276 
7 =0.635 =0.429 =0.531 =0.276 
9 =0.557 =0.647 =0.134 =0.236 
11 =0.118 =0.134 =0.465 =0.312 




5 =0.538 =0.367 =0.184 =0.298 
7 =0.751 =0.287 =0.789 =0.309 
9 =0.251 =0.621 =0.472 =0.284 
11 =0.092 =0.391 =0.398 =0.361 
13 =0.120 =0.294 =0.524 =0.582 
 
Table 12. Summary of p-values obtained from the statistical analysis of exploratory 
motor activity. Statistical analysis was performed by ANOVA-General Linear Model 
repeated measures. 
  





4.2.6 The reduction in R6/2 brain weight is not increased by the genetic ablation of 
Dbc1 gene 
At the end of the behavioural study, the mice were sacrificed at 15 weeks of age and 
the brains weighed. As expected, R6/2 brains weighed significantly less than those of 
WT mice (p<0.0005). Unfortunately, the genetic ablation of Dbc1 had no effect on R6/2 




Figure 51. Effect of Dbc1 knock-down and knock-out on brain weight in R6/2 mice. 
Brain weight measured at 15 weeks of age in WT (22), Dbc1+/- (19), Dbc1-/- (18), R6/2 










Table 11. Summary of p-values obtained from the statistical analysis of brain weight 
measurements. 
  





4.3 Cholesterogenic enzyme dys-homeostasis is not corrected by the ablation 
of Dbc1 gene in R6/2 mice 
Levels of cholesterol biosynthetic enzymes have been reported to be decreased in 
R6/2 mice (Valenza et al., 2007), and several studies have already shown a decrease in 
the expression of cholesterol synthesis enzymes in HD. It has been suggested that this 
is a result of mHTT perturbing the transcriptional activity of a master regulator of 
cholesterol synthesis SREBP-2 (Valenza et al., 2005; 2007; 2010). 
The sterol regulatory element-binding protein (SREBP) transcription factor family is a 
regulator of lipid and sterol homeostasis in eukaryotes. In mammals, SREBPs are able 
to promote the expression of lipogenic and cholesterogenic genes and to facilitate fat 
storage. It has been demonstrated that SREBP is an in vivo target of SIRT1 (Ponugoti et 
al., 2010), and the interaction between SIRT1 and SREBP was increased during fasting 
and decreased upon feeding. Consistent with this, SREBP acetylation levels were 
decreased during fasting in mouse liver (Ponugoti et al., 2010). Interestingly, a 
modulation of SIRT1 activity results in changes in SREBP ubiquitination, protein 
stability, and target gene expression. In addition, chemical activators of SIRT1 inhibit 
SREBP target gene expression in vitro and in vivo, correlating with decreased hepatic 
lipid and cholesterol levels and attenuated liver steatosis in diet-induced and 
genetically obese mice (Walker et al. 2010).  
Therefore, we checked if an increase of SIRT1 activity, due the ablation of Dbc1 gene, 
might have an effect on the expression of cholesterol biosynthetic genes. 
The expression of cholesterogenic enzymes was measure by Taqman qPCR assays. 
DBC1 genetic ablation had no effect on the expression of cholesterogenic enzymes in 





WT mice (Fig. 52), while the R6/2 genotype had a statistically significant effect on the 
expression of all cholesterogenic enzymes examined (Fig. 53) 
Taken together, these results suggest that the expression of enzymes responsible for 
cholesterol synthesis is not affected in Dbc1+/- and Dbc1-/- mice. This may be because 
DBC1 and SIRT1 do not regulate cholesterol synthesis, or because a compensatory 
mechanism has acts to maintain the levels of cholesterol biosynthetic genes after DBC1 
ablation. 
  







Figure 52. The mRNA expression levels of 7 cholesterogenic enzymes in 9 week old 
cortex from WT, Dbc1+/- and Dbc1-/- mice. Expression levels were normalised to the 
housekeeping genes Atp5b and Canx and expressed as fold change of WT levels ± SEM. 
n = 8 / genotype. 
  









Figure 53. The mRNA expression levels of 7 cholesterogenic enzymes in 9 week old 
cortex from WT, Dbc1-/- , R6/2 and Dbc1-/-::R6/2 mice. Expression levels were 
normalised to the housekeeping genes Atp5b and Rlp13a and expressed as fold change 
of WT levels ± SEM. n = 8 / genotype.  
  





4.4 General comments 
Deleted in breast cancer 1 (DBC1) is a cellular factor that binds SIRT1 and regulates its 
deacetylase activity by directly interacting with the SIRT1 deacetylase domain. This 
interaction inhibits the ability of SIRT1 to deacetylate its specific substrates. Our 
objective was to explore the effect of Dbc1 ablation on SIRT1 activity and to assess 
whether an increase in SIRT1 activity, resulting from Dbc1 ablation, could improve HD-
related phenotypes in a mouse model of HD. Therefore, we crossed R6/2 transgenic 
mice with mice in which DBC1 had been reduced or ablated to evaluate whether the 
increase in SIRT1 activity had a beneficial impact on disease progression in this HD 
mouse model.  
A characterisation of Dbc1 knock-out mice shows that the genetic ablation of DBC1 
resulted in a significant decrease of DBC1 both at mRNA and protein level in the brain. 
Additionally, reduction or removal of DBC1 protein did not affect the expression of all 
Hdacs and Sirtuins or the expression of cholesterogenic enzymes in the brain. 
Moreover, loss of DBC1 on WT background resulted in a considerable increase in SIRT1 
activity in the whole brain. Surprisingly, despite the ablation of DBC1, the SIRT1 
function impairment remain unchanged in R6/2 mice. In line with these results, we did 
not detect any effect on the onset and progression of a wide range of behavioural, 
molecular and pathological HD-related phenotypes. Therefore, we conclude that DBC1 
ablation does not modify disease progression in R6/2 mice. 
 





Chapter 5 Discussion 
5.1 Effect of Huntington’s disease on SIRT1 function 
The identification of SIRT1 and its involvement in lifespan extension and cellular 
protection from aggregation-prone proteins (Morley and Morimoto, 2004; Muchowski 
and Wacker, 2005; Douglas et al., 2009) has catalysed scientific attention as a 
promising therapeutic target for neurodegenerative disorders. Neurodegenerative 
disorders are complex diseases with many underlying pathways, and SIRT1 is a 
molecule with numerous different substrates in the cell. Therefore, it is not surprising 
that SIRT1 is involved in neurodegenerative disorders. The first study demonstrating 
the connection between SIRT1 and HD shows that the neuronal dysfunction 
phenotypes induced by mutant polyglutamine in Caenorhabditis elegans can be 
rescued by the overexpression of Sir2.1 (the homolog of SIRT1 in C. elegans) or 
treatment with an activator of SIRT1 (Parker et al., 2005). 
Recent studies have shown that the overexpression of Sirt1 can significantly reduce 
mHTT-induced toxicity in HD mouse models, improving motor function and reducing 
brain atrophy (Jeong et al., 2011; Jiang et al., 2011). These findings support a 
neuroprotective role of Sirt1 overexpression in mouse models affected by Huntington’s 
disease. However, the impact of this pathology on SIRT1 function has not been 
comprehensively investigated. 
 In the present study, we provide insight into the mechanisms behind the tissue-
specific regulation of SIRT1 activity over time and in different brain regions in WT mice. 
Furthermore, we showed that a progressive impairment of SIRT1 activity in different 
brain regions of HD mice is linked to an altered phosphorylation profile of SIRT1. To 





monitor SIRT1 activity in the brain, we analysed the acetylated status of P53 by 
performing immunohistochemistry on nuclei isolated from both R6/2 and HdhQ150 
mice together with their littermates. It is interesting to note that despite the different 
rate of disease progression that characterises these two models, we did not detect an 
alteration in SIRT1 function in the presymptomatic stages in both models. SIRT1 
activity was overtly compromised by 9 weeks of age in the R6/2 mice and at 22 months 
in HdhQ150 mice. This was not caused by SIRT1 sequestration into mHTT inclusions as 
we failed to detect any co-localization between SIRT1 and mHTT by 
immunohistochemistry. To further support this finding, we did not detect any variation 
in SIRT1 levels between HD and WT mice. These data suggest that mHTT can alter 
other mechanisms involved in the control of SIRT1 activity. 
 The role of post-translational modifications in the regulation of SIRT1 activity has 
been the subject of several studies and phosphorylation has been described as a major 
control PTM mechanism (Sasaki et al., 2008). It has been shown that kinases such as 
JNK1 and CK2 can phosphorylate SIRT1 thereby increasing its nuclear deacetylase 
activity (Nasrin et al., 2009; Zschoernig and Mahlknecht, 2009), as well as JNK1 
phosphorylation has also been shown to induce SIRT1 ubiquitination and proteasomal 
degradation (Nasrin et al., 2009). Therefore, to understand the effect of mHTT on 
SIRT1 function, we monitored the phosphorylation status of SIRT1 in mice affected by 
Huntington’s disease. Performing SIRT1 immunoprecipitation from half brains of R6/2 
mice at 9 weeks and HdhQ150 homozygous mice at 22 months of age, we detected an 
increased status of SIRT1 phosphorylation in HD mouse models.  This might indicate 
that the impairment in SIRT1 function in the brain of HD mice may be related to an 
altered phosphorylation profile. As mentioned previously, MpM2 antibody (used to 





detect the phosphorylation status of SIRT1) is able to detect only the phosphorylation 
on Serine and Threonine residues followed by Proline (S/T-P sites) present on any 
protein and it is not specific for any particular phosphorylation sites. Therefore, it 
cannot detect the activity of any specific kinase or phosphatase. Overall these results 
suggest that mHTT might, indirectly, affect SIRT1 activity. Indeed, we showed that the 
impairment of SIRT1 function in the brain of HD mice is not related to a sequestration 
into mHTT inclusions but we cannot exclude that several kinases or phosphates, that 
control the phosphorylation status of SIRT1, can be impaired from the interaction with 
mHTT aggregates.  
Despite the huntingtin gene and protein is widely expressed in the human body, HD is 
largely restricted to the brain. As said previously, one of the neuropathological 
hallmarks of Huntington’s disease is the striatum specificity and the disease 
progression can involve also other brain regions. Since, the results from half brain can 
mask the HD effects at the single brain regions level, we extended our analysis of SIRT1 
phosphorylation status and SIRT1 function to the striatum, cerebellum and cortex. 
Consistent with the half brain data, we did not detect any difference in the 
phosphorylation status of SIRT1 in the early stage of the disease in the single brain 
regions between WT and HD mouse models. Interestingly, the levels of SIRT1 
phosphorylation remain unchanged in the cortex with age. Analysing striatum and 
cerebellum, we found an opposite pattern of phosphorylation between them; 
surprisingly, we detected a reduction of phosphorylation status of SIRT1 in the 
striatum of both R6/2 (9 weeks) and HdhQ150 homozygous (22 months) mice 
compared to WT, while cerebellum was characterized by an increase of SIRT1 
phosphorylation in both HD mouse models as compared to WT littermates. These data 





further confirm an altered status of SIRT1 phosphorylation in presence of mHTT and 
with disease progression; moreover is interesting to see how the alteration follows an 
opposite pattern between striatum and cerebellum.  
To figure out if the altered pattern of SIRT1 phosphorylation in striatum and 
cerebellum of HD mice was related to an impairment of SIRT1 function, we isolated 
nuclei from both these brain regions of R6/2 and WT mice to perform an 
immunostaining and to monitor the acetylated status of P53. Interestingly, we 
detected a reduction in the level of AcP53 in striatum of WT mice from 4 to 14 weeks, 
consistent with an increase of SIRT1 activity with age. We did not detect the same 
increase in the striatum of R6/2 mice. When we analysed the acetylation status of P53 
in the cerebellum, we could not find any change in WT mice but we found a significant 
increase of AcP53 in R6/2 mice from 4 to 14 weeks of age, corresponding to a 
progressive impairment of SIRT1 activity with age. Taken together, these data show for 
the first time the existence of different mechanisms to regulate SIRT1 activity in 
different brain regions of WT mice. The induction of SIRT1 activity in the striatum and 
the unchanged level of SIRT1 function in the cerebellum with age led us to monitor the 
phosphorylation status of SIRT1 in WT mice in both tissues at 4, 9 and 14 weeks.  The 
SIRT1 immunoprecipitation from WT mice reveals a change in the phosphorylation 
status of SIRT1 in the striatum with age, suggesting that in the striatum the change in 
the phosphorylation status of SIRT1 with age can be related to an induction of SIRT1 
activity. Cerebellum showed a constant phosphorylation status of SIRT1 in WT mice 
with age, consistent with an unchanged SIRT1 activity between 4 and 14 weeks of age. 
 The list of SIRT1 substrates and targets is continuously growing and many of 
them are located in the nucleus. We have already mentioned the ability of the 





phosphorylation to induce the nuclear localization of SIRT1 promoting the interaction 
with its substrates (Nasrin et al., 2009). To check if the mis-regulation of SIRT1 
phosphorylation could affect its nuclear localization, we performed a nuclear and 
cytoplasmic fractions from striatum and cerebellum of R6/2 and WT mice at 9 and 14 
weeks of age. Interestingly, we did not detect any difference in the distribution of 
SIRT1 at any age between R6/2 and WT mice in both striatum and cerebellum. These 
results suggest that mHTT does not affect the subcellular distribution of SIRT1 and 
further support a link between regulation of SIRT1 activity and its phosphorylation 
levels.   
 Our finding that the phosphorylation status of SIRT1 is altered in HD mice further 
supports this central role for phosphorylation in the regulation of SIRT1 activity. 
Interestingly, despite the impairment in SIRT1 activity detected in both the striatum 
and cerebellum of HD mice, the phosphorylation level of SIRT1 was altered in opposing 
directions in these two brain regions, suggesting the existence of a tissue-specific 
regulation of SIRT1 via phosphorylation. This prompted us to further investigate the 
relationship between SIRT1 phosphorylation and its activity and this led to the 
identification of a striatum-specific phosphorylation-dependent induction of SIRT1 
activity between 4 and 9 weeks of age in WT mice, which does not take place in the 
cerebellum. In light of these new findings, we can now interpret differential SIRT1 
phosphorylation between the striatum and cerebellum of HD mice, suggesting that in 
physiological condition SIRT1 activity is induced in the striatum between 4 and 9 weeks 
(Fig. 53 A), whereas it remains constant in the cerebellum. The presence of mHTT can 
block this induction process in the striatum and cause a reduction in normal SIRT1 





function in the cerebellum resulting in an impairment of SIRT1 activity in both brain 
regions. 
 In an attempt to rescue this SIRT1 deficiency, we crossed R6/2 mice with Dbc1KO 
mice, as DBC1 has been reported to be a negative regulator of SIRT1 via direct 
interaction with its deacetylase domain (Escande et al., 2010). Strikingly, despite a 
significant upregulation of SIRT1 activity in Dbc1KO mice, the Dbc1::R6/2 double 
transgenic mice showed the same SIRT1 impairment as R6/2 mice, suggesting  that 
mHTT is altering key regulatory events that lie outside the inhibitory circuit controlled 
by DBC1. As a result of this, we did not detect any improvement on the onset and 
progression of several behavioural and pathological HD-related phenotypes. 
 In contrast to DBC1, AMPK-α1 has been reported to positively regulate the 
activity of SIRT1 by inducing SIRT1 activation through its dissociation from DBC1 
(Escande et al., 2012; Lau et al., 2014). Interestingly, our co-immunoprecipitation 
experiments revealed an increased interaction between DBC1 and AMPK-α1 in the 
striatum of HD mice, which might point to a rescue attempt by the damaged system. 
Nevertheless, our immunohistochemical analysis on the cellular distribution of AMPK-
α1 showed that AMPK-α1 is aberrantly distributed between the nucleus and the 
cytoplasm of R6/2 mice both in the striatum and the cerebellum, suggesting this event 
might be co-causal to the impairment of SIRT1 function (Fig. 53 A). In fact, we observed 
a delayed accumulation of AMPK-α1 in striatal nuclei of R6/2 mice that might impede 
SIRT1 activation, whereas AMPK-α1 nuclear accumulation in the cerebellum of R6/2 
mice was anticipated by 9 weeks of age, maybe trying to reduce the inhibition dictated 
by mHTT. To support the existence of a striatum-specific regulatory circuit linking 
these 3 proteins in the induction of SIRT1 activity with age, our analysis of mRNA and 





protein expression levels provided a complete picture in which it is possible to observe 
that in normal WT conditions the mRNA expression levels of Sirt1, Dbc1 and Ampk-α1 
are downregulated between 4 and 9 weeks of age and remain such through to 14 
weeks of age. Consistently, the protein level of AMPK-α1 is increased during the same 
time frame, suggesting that the protein might be stabilised, and that this could then 
lead to the induction of SIRT1. As a consequence of this induced activity with age, the 
level of SIRT1 could become stabilised, hence providing a negative feedback for Sirt1 
transcription. Interestingly, in the striatum of R6/2 mice, the stabilization/upregulation 
of AMPK-α1 does not take place, maybe due to an increased interaction with DBC1, 
and consequently this may lead to a failure in the induction of SIRT1. Therefore, SIRT1 
activity is not stabilised and the feedback to lower the transcription level of SIRT1 is 
not transmitted. In the cerebellum the expression analysis also supports our 
hypothesis of an impairment in SIRT1 activity in R6/2 mice which is under the control 
of a different regulatory mechanism, that is not age-dependent and does not require 
the induction of SIRT1, as the protein would already be fully functional. We propose a 
model whereby disease progression leads to altered SIRT1 phosphorylation status. As a 
consequence, SIRT1 activity is reduced and P53 cannot be deacetylated thereby 










Figure 54 A. Proposed model for the striatum-specific regulation of SIRT1 via 
phosphorylation in WT mice and for the impairment in SIRT1 activity in HD brain. (A) 
In WT striatum the change in SIRT1 phosphorylation status between 4 and 9 weeks of 
age induces an increase in SIRT1 activity followed by a reduction of acetylated P53. WT 
striatum show a nuclear accumulation of AMPK-α1 at 9 weeks supporting a role for 
this kinase in the activation process of SIRT1 (AMPK-α1 is not the kinase involved in the 
change in SIRT1 phosphorylation status detected here, as the MpM2 antibody can 
recognise only the Ser/Thr-Pro residues and AMPK-α1 is able to phosphorylate only 
Ser/Thr residues not followed by proline). AMPK-α1 is present in the nucleus at 9 
weeks and is proposed to activate SIRT1 through a mechanism independent of DBC1. 
The down-regulation of the mRNA level of Sirt1, Dbc1 and Ampk-α1 from 4 to 9 weeks 
of age is consistent with these three proteins being partners in the same regulatory 
circuit. In the HD condition the strong reduction in SIRT1 phosphorylation impedes the 
induction of SIRT1 activity. There is a greater interaction between AMPK-α1 and DBC1 
which may result in the cytoplasmic retention of AMPK-α1, inhibiting the activation of 
SIRT1, and/or promoting a futile rescue attempt by preventing DBC1 from binding to 
SIRT1. 








Figure 54 B. Proposed mechanisms of the striatum-specific regulation of SIRT1 via 
phosphorylation in WT mice and its impairment in R6/2 mice, and model for the 
impairment of SIRT1 activity in HD brain Disease progression in HD leads to a 
progressive alteration in SIRT1 phosphorylation.  An altered phosphorylation status 
causes an impairment in SIRT1 function, which results in an increase in P53 activity 
which may contribute to neuronal dysfunction and ultimately cell death. 
  





In conclusion, our data provide two major new findings. First, we showed that the 
mechanisms behind the tissue-specific regulation of SIRT1 activity are different 
between brain regions e.g. striatum and cerebellum. For the first time, we were able to 
describe a striatum-specific phosphorylation dependent mechanism of induction of 
SIRT1 activity with age in WT mice. 
Second, we provide the first evidence of a progressive impairment of SIRT1 activity in 
two different HD mouse models. Given that SIRT1 has been proposed to play a central 
role in metabolism and longevity, loss of SIRT1 activity may contribute significantly to 
disease progression in HD. 
5.2 Future work 
Recent studies have shown that the overexpression of Sirt1 can reduce mHTT-induced 
toxicity in HD mouse models, improving motor function and reducing brain atrophy 
(Jeong et al., 2011; Jiang et al., 2011). Moreover, we provide the first evidence of a 
progressive impairment of SIRT1 activity in two different HD mouse models and that 
the loss of SIRT1 activity may contribute significantly to disease progression in HD. 
Taken together, these results suggest that the pharmacological targeting of SIRT1 to 
enhance its activity may provide a new therapeutic opportunity for Huntington’s 
disease. The development of SIRT1 activators with high specificity for SIRT1 may be a 
promising approach for the treatment of Huntington’s disease. The high homology of 
SIRT1 with all the other sirtuins makes the development of specific compounds for 
SIRT1 very difficult.  
Several rational strategies based on the available protein structure and the catalytic 
pathways have been designed to develop small molecules (Sauve et al., 2009). One 
strategy involves designing resveratrol-like molecules, which has not yielded successful 





results as the in vivo mechanisms that control the activation of SIRT1 is not fully 
understood. Another approach aims to increase the cellular levels of NAD+ in order to 
activate SIRT1 function. This approach has the advantage of harnessing a natural 
metabolic pathway to enhance SIRT1 functions. Moreover, naturally occurring 
metabolites present the least risk of toxicity. The efficacies of agents that have been 
used to enhance NAD+ are still questionable. Indeed, NAD+ enhancement affects a host 
of other physiological pathways, hence the approach is not specific to SIRT1. A third 
strategy currently in the proof-of-principle stage designated nicotinamide derepression 
is based on countering the inhibitory effect of nicotinamide on sirtuins by designing 
molecules that are antagonistic to nicotinamide. This approach is still in its infancy and 
has not provided compounds with desired potency. 
In the present study, we also showed that a progressive impairment of SIRT1 activity in 
different brain regions of HD mice is linked to an altered phosphorylation profile of 
SIRT1. As consequence, in the future work will be important to determine the 
kinases/phosphatases involved in the regulation of SIRT1 activity in different brain 
regions in order to develop compounds that can act synergistically with SIRT1 
activators, act as novel SIRT1 inducers that bypass the impairment or restore this 
process by as-yet unidentified mechanisms.  
5.3 Validity of SIRT1 as therapeutic target in HD: strengths and weaknesses 
An exciting aspect is that SIRT1 mediates neuroprotection against both acute and 
chronic neurological diseases. Several studies have shown that the activation of SIRT1 
can have beneficial effects in HD and also in many other neurodegenerative disorders, 
such as Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, multiple 
sclerosis and cerebral ischemia. 





The pathological hallmarks of Alzheimer's disease (AD) are the intracellular tangles and 
extracellular plaques in brain. The tangles, also known as neurofibrillary tangles, are 
formed by accumulation of insoluble tau proteins, and the plaques are deposits of β-
amyloid (Aβ) peptides. The protective effect of SIRT1 against AD was initially observed 
in caloric restriction studies, where caloric restriction reduced Aβ and plaque 
generation in the brains of transgenic AD mice (Patel et al., 2005; Wang et al., 
2005a). Moreover, recent studies show that either administration of resveratrol or 
overexpression of Sirt1 reduces Aβ levels both in vitro and in vivo (Chen et al., 
2005b; Qin et al., 2006b; Donmez et al., 2010). Sirt1 overexpression stimulates the 
production of α-secretase in neurons and mice (Donmez et al., 2010; Qin et al., 2006b). 
Increased levels of α-secretase enhance normal process of Amyloid precursor protein 
(APP), leading to decreased generation of toxic Aβ. In addition, SIRT1 also reduces the 
NF-kappaB pathway in microglia and decreases Aβ level (Chen et al., 2005b). 
Parkinson’s disease (PD) is a common neurodegenerative disease caused by the death 
of dopaminergic neurons of the substantia nigra in the midbrain. Sirt1 overexpression 
(Wareski et al., 2009) or activation by resveratrol (Okawara et al., 2007; Chao et al., 
2008; Albani et al., 2009) slows neuronal death as well as neurodegeneration in PD 
models both in vivo and in vitro (Donmez et al., 2012), indicating a neuroprotective 
role of SIRT1 against PD. 
Amyotrophic lateral sclerosis (ALS) is a chronic, fatal neurodegenerative disease, 
characterized pathologically by the death of motor neurons in the spinal cord and 
cortex, possibly induced by a deficiency in the enzyme superoxide dismutase 1 (SOD1) 
(Rosen et al., 1993). In the animal model of ALS where a mutant form of SOD1 is 
expressed, SIRT1 levels are upregulated in motor neurons (Kim et al., 2007). Sirt1 





overexpression protects neurons against toxicity induced by the mutant SOD1 in both 
cultured neurons and mouse brain (Kim et al., 2007). This protection corresponds to 
the increased deacetylation of p53. Resveratrol also enhances the protective effect of 
SIRT1 in a mouse model of ALS (Kim et al., 2007; Markert et al., 2010). 
Multiple sclerosis (MS) is a myelin sheath disease with lesions typically located in the 
brain, spinal cord or cranial nerves, and, most commonly, in the optic nerve. The 
causes of multiple sclerosis are not fully identified but likely arise from an autoimmune 
etiology; therefore, it is traditionally treated as an inflammatory disease. In a mouse 
model of multiple sclerosis, experimental autoimmune encephalomyelitis (EAE), SIRT1 
activation by SRT501 or SRT1720 maintains axonal density, prevents neuronal loss, and 
improves neuronal dysfunction (Shindler et al., 2007, 2010). SIRT1 inhibition with 
Sirtinol attenuates the neuroprotective effects of SRT501 (Shindler et al., 2010), 
suggesting a protective role of SIRT1 in multiple sclerosis.  
Ischemic stroke is a common neurological disease caused by the sudden reduction or 
cessation of blood flow to the brain, leading to infarction. The neuroprotective effect 
of SIRT1 was first reported in ischemic preconditioning and the SIRT1 activating 
compound resveratrol reduced neuronal injury of the hippocampus in ischemia in rats 
(Raval et al., 2006; Morris et al., 2011). Sirtinol, an inhibitor of SIRT1 activity, abolished 
the neuroprotection of preconditioning and resveratrol (Raval et al., 2006), indicating 
that SIRT1 plays a key role in mediating neuroprotection. This neuroprotective role is 
further supported by two studies (Chong and Maiese, 2008; Della-Morte et al., 2009) 
showing that SIRT1 activation reduces ischemic neuronal injuries. Another study 
showed that, in primary neuronal culture, pretreatment with NAD+ reduces neuronal 
death induced by oxygen-glucose deprivation, an in vitro model of ischemia (Wang et 





al., 2008). SIRT1 is necessary for NAD+ neuroprotection, as NAD+ treatment 
upregulates SIRT1 activity, and Sirt1 knockdown attenuates the protection mediated 
by NAD+ (Wang et al., 2008).  
 Although exciting discoveries have been made in SIRT1 neurobiology, important 
questions still remain to be answered. Indeed, we cannot exclude that the 
administration of compounds able to increase the activity of SIRT1 could show some 
limits. It’s known that SIRT1 is involved in different cellular processes and it can behave 
differently in different tissues (Fig. 54). Moreover, the number of SIRT1 substrates 
grows daily, making the situation more difficult because the pathways involved overlap 
with other proteins (Fig. 54). 
As SIRT1 elicits multiple divergent effects in the central nervous system and periphery, 
different outcomes might occur, depending on how, when, and where SIRT1 is 
activated. Although pharmacological or genetic activation of SIRT1 show many 
beneficial effects, making it an attractive drug target, we should not forget that SIRT1 
acts on many different downstream targets, which are involved in numerous biological 
activities. Drugs that can specifically activate SIRT1 need to be tested in HD 
mammalian models, in order to identify whether the benefits of these drugs are 
sustained. If so, clinical trials will be necessary to follow up and to address whether 














Figure 55. Interacting partners, substrates and downstream effectors of SIRT1. 
(Reproduced from Dimitrios and Wilhelm, 2006). 
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Sequence of SIRT1 protein with relative Ser-Pro and Thr-Pro residues detected by the 
MpM2 antibody. 
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